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Abstract 
 
Cancer is the result of the accumulation of genetic and epigenetic alterations in key genes, 
which ultimately lead to uncontrolled growth of mutated cells. Genetic alterations range 
from small base substitutions to large chromosomal structural rearrangements. Many 
cancer genomes carry tens to hundreds of somatic structural rearrangements, which may 
have functional consequences. However, the patterns and characterization of somatic 
rearrangements in human cancers are still in early stages. In this thesis, I describe the 
genomic landscape of somatic structural rearrangements in human pancreatic cancers. I 
then investigate the potential mechanisms involved in somatic rearrangement formation 
and test whether such rearrangements can be used as biomarkers to monitor patient 
therapy.  
 
 Chapter 1 - Introduction: This chapter is a broad overview of somatic structural 
rearrangements in human cancers, motivation for studying them, and their potential use 
for clinical applications.  
 
 Chapter 2 – A workflow to increase verification rate of somatic chromosomal 
rearrangements using high throughput next generation sequencing: I established a high 
throughput workflow to rapidly verify somatic structural variants and identify the exact 
location of breakpoints using benchtop next generation sequencing and computational 
tools. The workflow examined more than 300 predicted breakpoints and identified 
breakpoint location in more than 80% of somatic events at base level. The results 
demonstrated that next generation sequencing is comparable to the conventional Sanger 
sequencing and can complete the verification workflow in a shorter timeframe, enabling 
rapid validation of events. 
 
Chapter 3 – Patterns of somatic breakpoints may indicate repair mechanisms that 
were active or absent during the generation of genomic rearrangements: This chapter 
describes the spectrum of somatic rearrangements and breakpoints detected in 120 
primary pancreatic ductal adenocarcinomas genomes. The analysis includes 
characterization of the breakpoint junctions to infer which potential DNA repair processes 
are occurring. The results revealed that the majority of tumours exhibited repair of 
chromosome structural breaks using microhomology sugges
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mechanism of DNA repair in pancreatic cancer. Tumours with BRCA1 or BRCA2 gene 
mutations or with a high contribution of a BRCA-like mutational signature showed a higher 
frequency of somatic breakpoints with microhomology length 1 to 5 bp and lower 
frequency of breakpoints with a blunt end (0 bp) when compared to tumours harbouring 
BRCA wild type or low BRCA mutational signature. The similarity in breakpoint 
characteristics between tumours with BRCA mutation and BRCA mutational signature 
reinforce previous findings that a subtype of pancreatic tumour might have deficiency in 
the HR pathway and could respond to PARP1 inhibitors. Furthermore, the analysis of the 
DNA sequence surrounding the breakpoints revealed strong signal of A+Ts rich regions 
suggesting that the formation of somatic rearrangements could also be mediated by either 
retrotransposition activity or chromosomal fragile sites. Taken together, the analyses of 
breakpoint junctions highlighted that the formation of somatic rearrangements in 
pancreatic carcinogenesis is complex – potentially with more than one mechanism active 
within a cancer genome.  
 
 Chapter 4 – Identification of personalized DNA-based biomarkers for pancreatic 
cancer and the assessment of whether they can be used to monitor tumour burden and 
response to chemotherapy: In this chapter, I first evaluated the performance of sequencing 
and PCR based methods to detect ctDNA. Subsequently, I quantified ctDNA in the serum 
or plasma of the three pancreatic cancer patients. Little or no detection of ctDNA was 
observed in the analysed serum samples. For one patient, a tumour specific 
rearrangement was detected in the serum, and this patient had already presented with 
metastatic disease. Based on the results, it was hypothesized that ctDNA released from 
pancreatic cancer might be limited by: i) nature of pancreatic cancer; ii) the physiological 
location of the pancreas which could influence the amount of ctDNA released in the 
circulation, as the fragmented tumour DNA might be cleared by the liver and therefore 
reduced the opportunity to detect ctDNA in the circulation; iii) volume of plasma or serum 
used to isolate cfDNA; iv) the status of disease progression. In this analysis, the ctDNA 
was detected only in the sample collected at late stage pancreatic cancer (after the 
diagnosed of liver metastasis). Thus, in the context of pancreatic cancer disease, the 
quantification of ctDNA might be more suitable for recurrent disease, which has 
metastasized from the pancreas.  
 
 Chapter 5: I concluded my findings throughout my studies in Chapter 2, 3 and 4 
with a summary and future directions. 
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1 Chapter 1 
 
Introduction 
 
1.1 Genomic landscape of the cancer genome 
Over the last two decades it has become increasingly clear that cancer is initiated by the 
accumulation of genetic damage in key cellular pathways. This damage ranges from small 
point mutations affecting a single DNA base to large genomic rearrangements. Collectively, 
these mutations confer a set of key attributes common to cancer cells (Negrini et al., 2010) 
(Figure 1-1), also known as ‘the hallmarks of cancer’. The disruption of these biological 
processes by genomic alterations favours cancer progression leading to uncontrolled 
growth of mutated cells (Negrini et al., 2010; Stratton et al., 2009).  
 
 
Figure 1-1 The hallmarks of cancer. The hallmarks of cancer describe biological 
processes related either to functional capabilities or to the presence of stress in cancer 
cells. Figure adopted from Negrini et al. (Negrini et al., 2010). Image used with permission 
from Nature Reviews Molecular Cell Biology (License Number: 3506161060186). 
 
 Alterations present in the cancer genome typically arise sporadically in response to 
environmental and lifestyle exposure to mutagens or due to intrinsic replication errors 
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(somatic mutations). When these changes or mutations occur in key genes or pathways, 
the cell with these changes may acquire a survival advantage. This cell may begin to 
divide abnormally. Subsequent cells may acquire new mutations which may result in 
cancer formation. On the contrary, germline mutations arise less frequently, and 
individuals are more likely to have genetic predisposition than intrinsic mutations or may 
have inefficient repair machinery to repair changes caused by exposure to mutagens. 
Therefore, this increases their risk of developing cancer. These alterations come in many 
forms including base substitution, small indels (small insertions and deletions), large 
structural variation (SV; changes to the structure of DNA), copy number variation (gain or 
loss of DNA sequence), loss of heterozygosity (LOH, loss of one allele) and epigenetic 
lesion (changes in DNA methylation or histone modification). If these mutations or 
alterations occur in genic regions, they may have an effect on the function of the gene.   
 
 Mutated genes that confer growth advantages and are positively selected in the 
tissue to promote tumorigenesis are referred as driver genes. Mutations that do not 
contribute to tumorigenesis but at some point are carried along in the clonal expansion of 
cancer cells are referred as passenger mutations (Stratton et al., 2009). Examples of 
driver mutations are single base substitution in the KRAS oncogene in pancreatic and 
colon cancers (Edkins et al., 2006) which results in an activated KRAS protein, missense 
mutations in ARID1A gene in pancreatic cancer (Biankin et al., 2012), structural 
rearrangement forming BCR-ABL fusion gene in leukaemia (Nowell and Hungerford, 1960), 
amplification of EGFR gene in lung cancers (Cappuzzo et al., 2005) and epigenetic 
inactivation of p16 in breast cancers (Witcher and Emerson, 2009). In some cases, 
especially for tumour suppressor genes, both copies of a gene have to be altered (bi-allelic 
damage) in order to promote a cancer phenotype. This observation was initially described 
by Knudson as the “two hit” hypothesis. Knudson et al. (Knudson, 1971) conducted a 
statistical study in retinoblastoma and showed that in the non-hereditary form of 
retinoblastoma (somatic mutation) both alleles were required to be altered to develop 
tumour. By contrast, in the inherited form (germline mutation) the first alteration was 
inherited in the DNA and the second alteration led to tumour development.  
 
In this chapter, I focus on somatic structural rearrangements (also known as 
structural variation) in human cancers and how such genomic alteration could lead to the 
development of cancer. I describe the role of chromosomal structural rearrangements in 
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cancer genomes (a form of genomic instability), different mutational mechanisms and 
catastrophe events that might be associated with these rearrangements. 
 
1.2 Structural rearrangements 
By definition, structural rearrangements are alterations within the genome, which are 
typically larger than 1 kb (Feuk et al., 2006). Such alterations can result in different types 
of rearrangements such as deletion, novel sequence insertion, mobile-element insertion, 
tandem duplication, interspersed duplication, inversion, and translocation (Alkan et al., 
2011) (Figure 1-2). Deletion refers to the absence of a segment of DNA in a chromosome 
(Feuk et al., 2006). Novel sequence insertion and mobile-element insertion refer to 
DNA sequence inserted into a given location (Feuk et al., 2006). Tandem duplication and 
interspersed duplication involve duplication of a segment of DNA in a chromosome 
(Feuk et al., 2006). Inversion involves breakage inversion and re-insertion of a DNA 
segment into a chromosome (Feuk et al., 2006). Translocation involves exchange or 
attachment of different DNA segments with no extra or missing genetic information 
(balanced) or exchange in chromosome material resulting in extra or missing genes 
(unbalanced) (Feuk et al., 2006). 
 
 
 
Figure 1-2 Types of structural rearrangements in human cancer. The schematic 
depicts the different types of structural rearrangements in human cancer. The 
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advancement in sequencing technologies has led to discovery of small-scale insertions 
and deletions (<1 kb) referred to as indels as well as large structural rearrangements that 
can range from 1 kb – 5 Mb (Alkan et al., 2011). Coloured boxes represent read pairs from 
the tumour and dotted lines represent how the reads map back to the reference genome. 
Figure adopted from Alkan et al. (Alkan et al., 2011). Image used with permission from 
Nature Reviews Genetics (License Number: 3506170505158). 
 
1.3 Genomic features that may influence the formation of structural 
rearrangements in human cancers 
A number of genomic features have been shown to influence the occurrence of 
chromosomal rearrangements in cancers. Cancer-specific rearrangements can be 
triggered by: 
 
 Chromosomal fragile sites. Many studies have demonstrated that fragile sites are 
hotspots for DNA breakage and there is a strong association between chromosomal 
breakpoints and the location of fragile sites, suggesting that fragile sites may play a role in 
the formation of cancer-specific rearrangements (Dillon et al., 2010; Gandhi et al., 2010). 
For example, genes that span the FRA3B fragile sites show increased frequencies of 
deletions and translocations in cancers (Corbin et al., 2002; Inoue et al., 1997). 
Furthermore, the DNA sequence at fragile sites is found to be composed of the expansion 
of CGG repeats or AT-rich sequence (Fungtammasan et al., 2012).  
     
 Repetitive regions. Repetitive DNA sequence can be a source of genomic 
instability in human cancers (Ribeiro et al., 2004). The two main categories of repeated 
DNA sequences are tandem repeats (e.g. satellite DNA, microsatellite) and interspersed 
repeats (e.g. DNA transposons, retrotranspsons). Molecular analysis has shown that 
repetitive DNA sequence is associated with DNA breakage (Argueso et al., 2008). 
Extending this, repetitive DNA sequences have been reported to be involved in the 
formation of chromosomal alterations such as amplifications and DNA rearrangements in 
human cancers (Makela et al., 1992; Ribeiro et al., 2004). 
  
 Chromatin modification. Chromatin structures, including epigenetic alterations, 
have been associated with genomic rearrangements. For example, whole-genome 
sequencing analysis of human prostate cancer has suggested that DNA rearrangements 
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are likely to occur in genes that are clustered together within regions of open chromatin 
(Baca et al., 2013; Berger et al., 2011).   
 
1.4 Consequences of structural rearrangements in human cancers 
Most structural variants have been characterised at the molecular level. Functional studies 
have shown that these large variants can lead to serious consequences and play 
important roles in initiating cancer. For example:  
 
 Disruption of a gene. Large numbers of structural variants directly delete or 
rearrange sequences of key genes leading to a loss of function. For example, the tumour 
suppressor genes BRCA1 and BRCA2 are commonly disrupted by insertions or deletions 
resulting in protein truncations (Sadikovic et al., 2008).  
 
 Gene copy number alteration. The overall copy number of genes can lead to 
either a gain of function through increased copy number (amplification) or partial to 
complete loss of function of a gene. For example, amplifications of oncogenes (such as 
KRAS, MYC) and deletions of tumour suppressor genes (such as TP53, PTEN). These 
events can have functional effects in key pathways involved in tumorigenesis (Leary et al., 
2008). Copy number alterations can result in LOH, in which one allele is lost. Gain of the 
remaining allele can result in copy neutral LOH. Moreover, copy number changes may 
result in an altered level of expression of cancer-related genes in the tumour cells (Xing et 
al., 1999).  
 
 Formation of fusion genes. This occurs when two formerly separate genes are 
joined together through genomic rearrangements forming a fusion gene that confers a 
growth advantages on cancer cells (Stratton et al., 2009). An example is the Philadelphia 
chromosome in chronic myeloid leukaemia (CML) in which ABL gene on chromosome 9 
and BCR gene on chromosome 22 are joined juxtaposed to create mutant BCR-ABL1 
fusion gene. The chimeric protein encoded by this gene fusion alters tyrosine kinase 
activity and speeds up cell division (Nowell and Hungerford, 1960). Another example is 
EML4-ALK fusion gene in lung cancer in which chromosome 2 is broken in two locations 
and the resulting piece of DNA is inverted and re-inserted into the chromosome leading to 
the fusion of ALK and EML4 genes. This produces a fusion protein that is highly active in 
ALK kinase activity generating oncogenic effects (Soda et al., 2007).  
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1.5 Catastrophe events, DNA repair and mutational mechanisms associated with 
structural rearrangements 
Perturbed DNA damage repair enables tumour growth. In a normal cell, the cellular DNA 
damage response (DDR) machinery is capable of screening for DNA damage, removing 
altered DNA and restoring correct nucleotide sequence. However, cancer genomes 
frequently harbour a number of defects in the DDR machinery. The disruption of the DDR 
machinery allows damaged DNA to survive during cell cycles, thereby increasing the 
chance of tumorigenesis (Bartek and Lukas).  
 
With the advancement of genomic technologies, catastrophe events and 
mechanisms such as chromothripsis, kataegis, chromoplexy, and break-fusion-bridge 
(BFB) were identified to be associated with the formation of somatic rearrangements in 
cancer genomes. Here, I summarize what is known about these mechanisms and what 
features of the structural rearrangements may give us clues about the operative 
mechanisms or events in cancer genomes. 
 
Chromothripsis: This is a mechanism that generates a high number of 
rearrangements in a complex localized fashion and these complex rearrangements are 
formed by shattering one or few chromosomal regions in a single event that may lead to 
rapid cancer development. This phenomenon was first reported in the genome of chronic 
lymphocytic leukaemia (CLL) sample with a total of 42 rearrangements localized on the 
long arm of chromosome 4 (Stephens et al., 2011). Chromothripsis is identified by the 
following  key features (Korbel and Campbell, 2013): (1) a high number of rearrangements 
(clusters) are localized at a particular region within genome; (2) rearrangements show 
marked oscillation between two or three copy number states; (3) affected regions display 
segments with retained heterozygosity interspersed with LOH (e.g. regions of copy 
number 1 show LOH; regions with copy number 2 retain heterozygosity); (4) DNA 
shattering is typically originated from a specific haplotype; (5) the order and type of 
rearrangements are random. 
 
Kataegis: This is a localized hypermutation event characterised by clusters of C>T 
and C>G mutations at TpCpX trinucleotides on the same strand at particular regions along 
the genome (mutational thunderstorm) (Nik-Zainal et al., 2012). This phenomenon was 
first reported in the study carried out by Nik-Zainal et al. whereby the authors sequenced 
21 breast cancer genomes and observed clusters of mutations at specific regions along 
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the genome (‘kataegis’) visualised in ‘rainfall plot’. Of the 21 breast cancer, 13 (62%) 
revealed some extent of kataegis. Extending this study, Alexandrov et al. applied the same 
approach and analysed 30 different cancer types from whole genome and exome 
sequencing. Furthermore, it was noted that the regions of kataegis were co-localized with 
genomic rearrangements (Alexandrov et al., 2013; Nik-Zainal et al., 2012).  
 
Chromoplexy: This is a phenomenon first reported by Berger et al. (Berger et al., 
2011) - the authors observed frequent occurrence of large complex chains of 
rearrangements involving multiple genes in seven prostate tumours. These chain events 
were generated by the shuffling of broken DNA ends and subsequently re-joined randomly 
in a novel manner. In a recent study, the analysis of “chromoplexy” was expanded to 57 
prostate tumours and a computational method was developed to systematically detect 
chromoplexy events (Baca et al., 2013). The analysis revealed that many of these chains 
contained variable number of rearrangements (> 40 rearrangements), which lead to DNA 
deletions, and fusions genes located near rearrangements breakpoints.  
 
Break-Fusion-Bridge: Overexpression of oncogenes through gene amplification is 
frequently observed in cancer cells (Hillmer et al., 2011; Lo et al., 2002). This is known that 
BFB, a DNA replication based mechanism, accounts for such amplification. By its name, 
the cycles involve the breakage of chromosome followed by fusion and then “bridge” 
formation. Briefly, BFB begins with the telomere loss, followed by fusions of unprotected 
chromosomal sister chromatids ends. The fused chromosomes are separated during 
anaphase and forming a “bridge” and ultimately breaking as the centromeres are pulled in 
opposite direction. This process repeats for several cell division cycles resulting complex 
genetic combination with dramatic copy number increases. Furthermore, when the 
amplified regions harbour oncogenes, this can provide a growth advantage to cancer cells 
(Bunting and Nussenzweig, 2013). 
 
1.6 Detection of structural variation 
The combination of experimental studies and computational strategies has revealed 
extensive presence of large structural variants in cancer genomes (Feuk et al., 2006; 
Iafrate et al., 2004; Levy et al., 2007; Medvedev et al., 2009; Tuzun et al., 2005). Here, I 
describe a brief history of molecular biology approaches and genomic technologies to 
detect structural rearrangements.  
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 Structural rearrangements were first investigated by karyotyping. This technique 
examines chromosomes under a light microscope and is limited to the physical 
characteristic of chromosomes (such as length, size difference, and position of 
centromeres) (Heim and Mitelman, 1992; Warburton, 1991). Subsequently, various 
cytogenetic banding techniques such as G-banding, spectral karyotyping, and 
fluorescence in-situ hybridization were used to detect structural rearrangements including 
translocations, deletions, duplications, insertions and inversions (McNeil and Ried, 2000). 
The resolution of these later techniques is typically 1-2 Mb, and hence, they are not able to 
fully describe highly complex rearrangements. Simultaneously, the development of 
genome-wide array-based (e.g. array comparative genomic hybridization - aCGH (Pinkel 
et al., 1998) and targeted PCR based approaches (e.g. real-time quantitative PCR - 
qPCR) have allowed systemically screening of sub-microscopic unbalanced structural 
rearrangements with varying degrees of resolution (Dhami et al., 2005; Neill et al., 2010; 
Tagawa et al., 2004). For example, aCGH compares two labelled samples (test and 
reference) to a set of hybridization targets and qPCR screens for the targeted region of the 
genome. However, these techniques are limited to detect gain or loss of DNA material 
(such as deletions and amplifications) and do not detect event types which do not result in 
copy number changes (such as inversions). 
 
 More recent, the introduction of next generation sequencing technologies has 
expedited the interrogation process of structural variation and overcome some of the 
limitations encountered by the former techniques and also enabled us to identify the 
breakpoints of different event types at single nucleotide resolution (Kidd et al., 2008; 
McKernan et al., 2009; Shendure and Ji, 2008). 
 
1.7 Next generation sequencing 
Sequencing platforms  
Automated DNA sequencing has stemmed from the human genome project more than a 
decade ago. The growing demand of high throughput sequencing led to the development 
of next generation sequencing platforms in recent years. The advanced technologies have 
impacted the field of cancer genomics by dramatically increasing the pace of discovery of 
alterations in cancers. Here, I have grouped the next generation sequencing platforms by 
their sequencing scale throughput and summarized them in Table 1-1.  
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Table 1-1 Comparison of next generation sequencing platforms 
 Small-scale sequencing 
 Ion Torrent PGM* 
(Life Technologies) 
MiSeq 
(Illumina) 
Application Targeted DNA/RNA sequencing, 
copy number analysis, small RNA 
sequencing 
 
Small genome, amplicon, and 
targeted gene sequencing. 
Output per run  60-100 Mb 0.3-15 Gb 
Read length  400 bp 2 × 300 bp 
Run time 3.7 hr 5-65 hr 
*Based on Ion 314™ Chip v2 
 
 Medium-scale sequencing 
 Ion Proton™ System* 
(Life Technologies) 
NextSeq 500 
(Illumina) 
PACBIO RS II - 
SMRT sequencing 
(Pacific Bioscience) 
Application Whole genome, exome, 
transcriptome, targeted 
gene sequencing and 
more 
Whole genome, 
exome, transcriptome 
sequencing and 
more. 
De novo assembly, 
targeted sequencing, 
base modification, 
metagenomics 
Output per run  ~10 Gb 20-120 Gb 100-150 Mb/SMRT 
cell 
Read length  200 bp 2 x 150 bp > 8,000 bp (C3 
chemistry) 
Run time 2-4 hr 15-30 hr 90 min 
*Based on Proton I 
 
 Large-scale sequencing X Large-scale sequencing 
 HiSeq 2500 
(Illumina) HiSeq X Ten (Illumina) 
Application Whole genome, exome, 
transcriptome sequencing and more 
Whole genome sequencing 
Output per run  10-1000 Gb 1.6-1.8 Tb 
Read length  2 × 150 bp, 2 × 125 bp 2 × 150 bp 
Run time 7hr – 6 days < 3 days 
Gb – Giga base, Mb – Mega base, hr – hour 
 
To attain a comprehensive view of disease specific mutations in cancer genomes in 
particular structural rearrangements, whole genome sequencing is required to compare 
tumour and matched normal DNA of a patient to identify novel somatic structural 
rearrangements. Today, the most popular platform used is the Illumina HiSeq 2500.  
 
Briefly, Illumina platforms adopt sequencing by synthesis chemistry. Fragments of 
DNA are immobilized onto the flow cell surface. The fragments are exposed to DNA 
polymerase to synthesize the complementary strand. The double-stranded DNA is 
denatured and extended, priming occurs when the free end of a ligated fragment “bridges” 
over to a complementary oligo in the flow cell surface. The amplification process repeats 
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and occurs simultaneously forming millions of clusters across the flow cell surface. 
Sequencing begins with the incorporation of fluorescently-labelled deoxynucleotide 
triphosphate (dNTP) to the sequences of the nucleic acid chain during each cycle. For 
each dNTP incorporation, the fluorescent dye emits a signal to identify the base.   
 
As for the small-scale benchtop sequencers (such as Ion Torrent PGM and Illumina 
MiSeq), they are normally used in targeted sequencing applications such validation of 
somatic mutations or a predefined region of the genome. MiSeq uses similar chemistry to 
Illumina HiSeq 2500. Ion Torrent technology uses different sequencing chemistry. It uses 
semiconductor chip technology to detect hydrogen ions produced during DNA replications 
in real time. The semiconductor chip contains millions of wells capturing single stranded 
DNA molecule for sequencing. The sequencing process begins with DNA fragments 
attached to the surface of bead particles and then clonally amplified. The templated bead 
deposited into the wells on the semiconductor chip and followed by each of the four 
nucleotides is orderly introduced. When the nucleotide is incorporated into a single strand 
of DNA, a hydrogen ion is released. The ion senor records the change in pH of the 
solution indicating that the nucleotide has incorporated. 
 
 Overall, next generation sequencing technologies enable sequencing in a massive 
parallel manner allowing large number of samples to be sequence at a time. The use of 
such technologies facilitates efficient and economic genome wide readout on molecular 
level. The data obtained from next generation sequencing has much higher resolution, 
which can identify somatic structural rearrangements at nucleotide level.  
 
1.8 Large integrative cancer genome programs and databases 
In order to catalogue mutations in a broad range of cancer types, two large international 
consortiums have been established to coordinate the catalogues of mutations in a large 
number of cancer genomes around the world. They are the Cancer Genome Atlas (2011) 
(TCGA) and the International Cancer Genome Consortium (2010) (ICGC). The goals of 
these programs are to obtain comprehensive catalogue of somatic mutations in human 
tumours and cancer cell lines, identify repertoire of cancer genes as well as integrating 
somatic mutations with epigenomic and transcriptomic studies, functional and pathways 
analysis. Additionally, the collection of these somatic mutations is stored in public 
databases such as the ICGC data portal, COSMIC (Catalogue Of Somatic Mutations In 
Cancer) or HGMD (Human Gene Mutation Database).  
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 The Queensland Centre for Medical Genomics (QCMG) led by Prof. Sean 
Grimmond is part of ICGC. Australia’s contribution to ICGC is to sequence and analyse 
pancreatic and ovarian cancers enabling a deeper understanding of the mechanisms that 
lead to genomic instability and ultimately cancer. The Centre is committed to deliver and 
enable personalized medicine for the state of Queensland and Australia (www.qcmg.org). 
Collection of all tumour samples was coordinated via our collaborators at the Garvan 
Institute (Prof. A. Biankin – Pancreatic project) and Peter MacCallum Cancer centre (Prof. 
David Bowtell – Ovarian project). A total of 392 primary pancreatic ductal 
adenocarcinomas, 100 pancreatic neuroendocrine tumours and 93 ovarian tumours 
underwent genome sequencing analysis at QCMG and were submitted to the ICGC data 
portal (www.icgc.org | Numbers correct on January 2015).  
 
1.9 Pancreatic cancer 
Epidemiology of pancreatic cancer 
Pancreatic cancer is an aggressive disease with a poor prognosis and is the 4th largest 
cause of cancer death in Western countries. Each year over 200,000 people are 
diagnosed with the disease worldwide. Australia has one of the highest incidence rates of 
pancreatic cancer in the world (Figure 1-3). The mortality rate of pancreatic cancer is also 
one of the highest among the major cancers and the survival rate has not improved over 
the last 40 years with a median survival of 6 months. Only 5% of patients diagnosed with 
pancreatic cancer survive more than 5 years (Jemal et al., 2010).  
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Figure 1-3 World incidence rates of pancreatic cancer. The data was collected from 
Cancer Research UK in year 2012. This section was last reviewed and updated on 11 
June 2014.  
 
There are two main types of pancreatic tumours, exocrine (derived from enzyme 
producing cells) and endocrine (derived from hormone producing cells). The most common 
form of pancreatic tumour is exocrine type, which account for more than 95% of all 
pancreatic tumours. Pancreatic ductal adenocarcinoma (PDAC) is the most common 
exocrine tumour, making up 90% of all exocrine tumours. The remaining is made up by 
acinar cell carcinoma, intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, 
pancreatoblasma, serous cystadenocarcinoma and solid psuedopaillary neoplasm.  
 
On the other hand, pancreatic endocrine tumours make up approximately 5% of all 
pancreatic cancers and consist of two subtypes: neuroendocrine tumours and islet cell 
tumours. In this project, the research focuses on exocrine PDAC. 
 
1.9.1 Treatment options 
At present, there is no clear screening method to detect pancreatic cancer at an early 
stage. Due to the lack of early warning symptoms, patients are normally diagnosed at late 
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stages and the disease has metastasized upon diagnosis. Large tumours can be detected 
by computed tomography scan, magnetic resonance imaging and endoscopic ultrasound 
(Klapman and Malafa, 2008). 
 
The only curative treatment is surgery to resect the tumour, followed by 
chemotherapy. However, only 7-20% of patients present with operable tumour. The 
remaining non-resectable patients present late stages of the disease are offered palliative 
chemotherapy that usually involves the chemotherapeutic agent Gemcitabine (GEM) as 
first line therapy (Saif, 2006). GEM response is only seen in 20-30% of patients and 
chemoresistance is rapidly acquired. The failure of current treatment regime indicates that 
there is a need to increase our understanding of this disease and develop alternative 
treatments for the pancreatic cancer patients.  
 
1.9.2 Molecular characteristic of pancreatic cancer 
It is estimated that 90% of pancreatic tumours arise from precursor lesions of DNA during 
life and these damages often arise sporadically. The exact mechanism of pancreatic 
cancer development is not yet fully understood but studies have identified key genetic 
mutations and signalling pathways associate with its tumorigenesis (Biankin et al., 2012; 
Campbell et al., 2010; Jones et al., 2008; Wang et al., 2012).  
 
The most common genetic lesions that are found in most PDAC are mutations of 
p16INK4A(CDKN2A), TP53 and SMAD4(DPC4) tumour suppressor genes (TSG) and the 
KRAS oncogene. Inactivation of TSG or activating mutations of oncogenes could create a 
“domino effect”, where loss of tumour suppressor genes or activating mutations of 
oncogenes can affect several cellular pathways that regulate cell-cycle, cell survival, 
invasion and metastases (Raimondi et al., 2009).  
 
1.9.3 TSG in PDAC 
p16INK4A tumour suppressor protein is inactivated in more than 90% of sporadic pancreatic 
cancer (Caldas et al., 1994). It is located on chromosome 9p21, encoded by the CDKN2A 
gene. CDKN2A is an inhibitor of cyclin-dependent kinase 4, when active, it triggers 
retinoblastoma phosphorylation to induce cell cycle arrest in G1 and G2 phases (Schutte 
et al., 1997; Sherr, 1996). The mechanisms of CDKN2A inactivation include intragenic 
mutation, deletion and hypermethylation of p16 (Schutte et al., 1997). Inactivating 
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mutations of TP53 genes are also found in 50-75% of pancreatic cancer. p53 has multiple 
tumour suppressing functions and play a crucial role in cell cycle progression by inducing 
growth arrest or apoptosis in normal cell when the DNA is damaged (Kalthoff et al., 1993; 
Levine, 1997). 
 
Another TSG frequently mutated in pancreatic ductal adenocarcinoma is 
SMAD4(DPC4), which is a member of SMAD family of signal transduction proteins which 
is lost in 50% of pancreatic cancer (Hahn et al., 1996). It acts as a co-activator and 
mediator in transforming growth factor (TGF-β) signalling pathway by forming complexes 
with other SMAD proteins, then translocated into the nucleus and regulates the expression 
of target genes (Heldin et al., 1997). In the context of cancer, the inactivating mutations of 
SMAD4(DPC4) may disrupt TGF-β signalling pathway and then up-regulate the 
expression of cancer-associated genes to facilitate cancer tumorigenesis. 
 
1.9.4 Oncogenes in PDAC 
Mutations of KRAS oncogene are present in more than 90% of pancreatic cancers 
(Pellegata et al., 1994). This gene is mutated in different positions in its sequence codon, 
for example, codon 12, 13 or 61. The KRAS gene encodes a protein with GTPase activity 
that mediates signal transduction pathway regulating cell cycle progression and cell 
proliferation. The single amino acid substitution at codon 12, 13 or 61 leads to perpetual 
activation of signalling with the loss of GTPase activity locking KRAS into an active state.  
 
1.9.5 Mutational landscapes and pathways in pancreatic cancer 
Sequencing efforts have revealed mutational landscape of pancreatic cancer (Biankin et 
al., 2012; Jones et al., 2008; Wang et al., 2012). The complexity of the genetic alterations 
in PDAC was first described in the study conducted by Jones et al. (Jones et al., 2008). 
Genomic analysis of more than 900 genes across 24 PDAC xenograft and cell lines have 
shown that these mutations lead to recurrent perturbation of 12 core signalling pathways 
which frequently altered (67-100%) among the cohort of 24 patients (Figure 1-4).  
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Figure 1-4 Signalling pathways and processes. (a) The 12 core signalling pathways 
and processes genetically altered in most pancreatic cancers. (b) and (c) are the two 
pancreatic cancers studied in Jones et al (Jones et al., 2008). The positions around the 
circles in (b) and (c) correspond to the pathways and processes in (a). This figure has 
illustrated that the common signalling pathways share a number of genes, for instance, the 
mutation in BMPR2 have disrupted both SMAD4 and Hedgehog signalling pathways in 
Pa10X (Jones et al., 2008). Image used with permission from Science (License Number: 
3527851309934).   
 
To date, the largest study of mutations in PDAC involved exome sequencing and 
CNV analysis of 142 PDAC primary tumours (Biankin et al., 2012). The vast majority of 
mutations identified by Biankin et al. are somatic in nature (such as missense, nonsense, 
splice site, insertion/deletion, non-silent and silent). The study has confirmed the 
importance of known mutations in PDAC such as KRAS, TP53, CDKN2A, SMAD4, MLL3, 
TGFBR2, ARID1A and SF3B1 and uncovered novel significant mutated genes such as 
EPC1 and ARID2 (involved in chromatin modification), ATM (implication in BRCA-
mediated DNA damage repair mechanisms) and many more which occur at low frequency. 
Pathway analysis also revealed that these novel genes were strongly associated with axon 
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guidance pathways. Additionally, recurrent mutations (SLIT2 and ROBO2) of axon 
guidance pathways were identified in 20% of the patients suggesting that this pathway 
might play a role in the pathophysiology of PDAC disease.   
 
1.10 Pan-cancer analysis 
Thousands of tumours of many types have been sequenced by TCGA and ICGC for the 
discovery of mutations to deepen our understanding of the nature of cancer genomes. 
Through these studies, we learnt that cancer genomes display unique spectrum of 
mutations within each cancer type. However, it is believed that a set of mutations (i.e. 
driver mutations) may involve in certain pathways and/or mechanisms that could be 
shared by more than one cancer type. As such, TCGA Research Network set up pan-
cancer initiative studies to identify possible common patterns shared by different cancer 
types. 
 
In 2013, the TCGA Research Network released a series of papers to compare the 
differences and similarities between tumours originated from different tissues 
(http://www.nature.com/ng/focus/tcga/index.html). One example of these studies was 
conducted by Kandoth et al. analysing 3,821 primary tumours across 12 cancer types 
(Kandoth et al., 2013). More than 600,000 somatic mutations were identified including 
missense, silent, nonsense, splice site, non-coding DNA, ‘non-stop’, and indels. Detailed 
analysis of the integrated data revealed 127 significantly mutated genes from known 
signalling and enzymatic processes across cancers and 66 of them were driver mutations. 
Furthermore, they learnt that the combination of driver mutations varies within individual 
patients. Hence, such studies provide new insights of the wide spectrum mutations in 
cancer genomes and their molecular composition.  
 
Taken together, the efforts of these emerging studies looking across different 
cancer types and/or individual patient tumour enable us to fully exploit the information of 
cancer genomics to (1) improve the development of prognostic/diagnostic biomarkers, (2) 
develop targeted therapeutic intervention, and (3) provide alternative directions for drug 
development and search more appropriate “druggable” target. 
 
1.11 Summary 
In summary, the study of genomic landscape (such as genomic instability and mutational 
mechanisms) using next generation sequencing holds great promise for restructuring the 
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way in which we treat cancer. In this thesis, I study somatic structural rearrangements in 
pancreatic cancer genomes using next generation sequencing. The study of somatic 
rearrangements in pancreatic cancer genomes is divided into 3 different aspects: 
genomics technologies and computational methods to detect and verify somatic 
rearrangements, genomics analysis of somatic rearrangements and DNA patterns in the 
region of breakpoints, and the utility of somatic rearrangements in personalized genomics 
medicine. Figure 1-5 detailed what will be investigated in the following chapters of this 
thesis. 
 
 
Structural Variation in Cancer 
Genomes 
Aim 1: Genomic technologies 
and computational methods 
•  Establish a high throughput 
verification workflow    
 
•  Evaluate tools for downstream 
somatic rearrangements 
verification analysis 
•  Assess the accuracy of next-
generation sequencing to 
identify rearrangements 
breakpoints location  
Aim 2: Data analysis 
 
 
•  Characterise the breakpoints 
using soft clipped and 
unmapped reads   
 
•  Study the patterns of 
breakpoints characteristics 
•  Identify consensus motifs by 
examining the DNA sequences 
surrounding breakpoints on the 
reference genome 
Aim 3: Personalized genomic 
 
 
•  Identify tumour specific 
mutations in patients 
•  Examine the sensitivity of 
instruments used for detection 
and quantification tumour 
specific mutation in serum 
•  Interpret the quantification with 
the course of therapy of patients 
 
Figure 1-5 An overview framework of the thesis. Aim 1 - Chapter 2: Genomics 
technologies and computational methods. This project presents a high throughput 
workflow, which can increase the verification rate of somatic rearrangements in cancer 
genomes. Aim 2 - Chapter 3: Data analysis. The project focuses on the characterization of 
somatic rearrangements and interpretation of data at large-scale to elucidate the potential 
mechanisms that contribute to the formation of somatic rearrangements. Aim 3 - Chapter 
4: Personalized genomic. The project aims to demonstrate the utility of tumour specific 
mutations as biomarker for pancreatic cancer diagnosis and therapeutic strategies.   
 
1.12 Hypotheses 
Cancer is a genetic disease, which often associates with genomic instability and DNA 
damage. It is hypothesized that the patterns of somatic breakpoints and the DNA 
sequence surrounding the breakpoints junctions can identify the DNA repair mechanisms 
underlying the formation of structural variation in pancreatic cancer genomes.  
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We further hypothesize that tumour specific mutations can be used as candidate 
biomarkers in pancreatic cancer. Tumour specific rearrangements and mutations in 
pancreatic cancer can be detected in cell-free circulating DNA of patients. These 
rearrangements and mutations can be used as personalized biomarkers to determine 
tumour burden and monitor patient response to therapy.  
 
1.13 Aims 
To address these hypotheses, the aims are to: 
  
1. Develop an approach utilizing next generation sequencing to rapidly capture and 
verify somatic chromosomal rearrangements in the genome of primary tumours and 
establish a high throughput genomic and computational workflow  
 
2. Identify the exact location of DNA breakpoints and characterise the breakpoints 
region that may indicate potential mechanisms that contribute to the formation of somatic 
rearrangements. 
 
3. Identify personalized DNA-based biomarkers for pancreatic cancer and assess 
whether they can be used to monitor tumour burden and response to chemotherapy 
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1.14 Significance 
The work presented here is to explore genomic data of pancreatic cancer. The aim of this 
study is to catalogue and verify large numbers of somatic chromosomal rearrangements 
detected by next generation sequencing. The resulting high-resolution catalogue of 
verified rearrangements and the sequence context of breakpoints together with other 
somatic mutations would provide clues of how somatic variants implicate in cancer 
establishment and maintenance. And lastly, we will evaluate the utility of verified somatic 
rearrangements and mutations as biomarkers in the serum or plasma of pancreatic cancer 
patients in the hope to develop an alternative approach to trace the course of the disease 
also during cancer treatment.   
 
More importantly, the work could show the potential of using next generation 
sequencing technology as a tool to understand different aspects cancer genomes. 
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2 Chapter 2 
 
A workflow to increase verification rate of somatic 
chromosomal rearrangements using high throughput next 
generation sequencing 
 
2.1 Introduction 
The ICGC project aims to catalogue the complete repertoire of somatic mutations, identify 
drivers of mechanism of cancer development and progression and improve therapy 
options to ultimately benefit patient’s outcome. QCMG is part of the ICGC (International 
Cancer Genome Consortium) and in 2014, we completed the sequencing and analysis of 
392 primary pancreatic ductal adenocarcinomas, 100 pancreatic neuroendocrine tumours 
and 93 ovarian tumours. During this process, the laboratory not only generated and 
analysed a large volume of sequencing data but also developed several bioinformatics 
tools to facilitate the genomics analysis of these tumours (Kassahn et al., 2013; Quek et 
al., 2014; Song et al., 2012). The sequence data was analysed by the QCMG to determine 
somatic base pair substitutions, indels, copy number changes and chromosomal structural 
rearrangements. Within this large initiative, my first results chapter specifically aimed to 
detect and verify somatic rearrangements obtained from whole genome sequencing data 
and create a comprehensive catalogue of high quality structural mutations.  
 
2.1.1 qSV 
There are five main methods to detect structural rearrangements: (1) discordant read pair, 
(2) soft clipping, (3) spilt read, (4) read depth and (5) sequence assembly (Alkan et al., 
2011; Wang et al., 2011). The first 4 methods utilize ‘comparison-versus-reference’ 
strategy, whereby next generation sequencing data is aligned to a known reference 
genome and then the genomic locations of potential structural rearrangement are 
estimated. The 5th method is based on sequence assembly, which joins DNA sequences 
with similarity and constructs into a larger census contig. At QCMG, we developed a tool 
named qSV to identify somatic rearrangements using 3 methods - discordant read pair, 
soft clipping and split read (Figure 2-1) (Patch*, Newell* and Quek* et al.  – manuscript in 
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preparation). The brief descriptions of the 3 methods incorporated in the detection tool are 
as follows:   
  
 1) Discordant read pair. Paired end sequencing data consists of two sequence 
reads, which should align to the genome at a known distance apart. The discordant read 
pair method assesses the distance and orientation of the two sequence reads and 
identifies read pairs in which distance and orientation of the read pairs are inconsistent 
with the reference genome. For example, deletion in which read pairs are mapped in the 
correct orientation but too far apart, or insertion in which read pairs mapped too close and 
inversion or tandem duplication where read pairs are in incorrect orientation (Alkan et al., 
2011). Other computational tools which use discordant read pair method include 
BreakDancer (Chen et al., 2009), DELLY (Rausch et al., 2012), VariationHunter 
(Hormozdiari et al., 2009) and PEMer (Korbel et al., 2009).   
 
2) Soft clipping. Soft clipping occurs if part of a read maps well, while the other end 
of the read does not align. The unaligned sequence is hidden but retained in the BAM file 
(known as soft clipping). In the case of breakpoints, the unaligned part of the sequence 
read will align to the other side of the breakpoint. This soft clipping method identifies 
clusters of reads, which have been soft clipped to detect breakpoints and then directly find 
the exact breakpoint of the structural rearrangements. Computational tools, which use the 
soft clipping method, are CREST (Wang et al., 2011) and Socrates (Schroder et al., 2014).   
 
3) Split read. The split read method can directly detect the breakpoints of structural 
rearrangements by mapping the read sequences to the reference genome with gap 
alignment. qSV uses split read logic – it performs a round of de novo assembly on all 
unmapped, abnormally mapped and clipped bases from reads, whose pair is mapped 
within +/- 1 Kb of putative breakpoint by qAssemble. The longest assembled contig is 
subjected to local alignment on the reference genome carried out using BLAT (Kent, 2002). 
This process increases breakpoint resolution as the larger assembled product is able to 
capture more of the complexity of a locus than soft clipping signature alone. Hence, the 
assembly of a longer contig enable the discovery of deletions and small insertions. 
Microhomology and non-template sequenced are calculated and refined for soft clipping 
breakpoints and generated where possible for events with discordant mapped pairs 
evidence only. 
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Computational tools such as DELLY (Rausch et al., 2012), PRISM (Jiang et al., 
2012), and Pindel (Grabherr et al., 2011) use split read algorithm to uncover structural 
rearrangements in human genomes.  
 
 Evidence of all the 3 methods increases the confidence that an event is real (Alkan 
et al., 2011). This strategy clusters different rearrangements with the same characteristic 
to support a potential structural rearrangement (Figure 2-1). 
 
Ref$genome$
Tumour$
Dele.on$
discordant$mapped$read$pair$
so6$clipping$
split$con.gs$from$
unmapped$reads$
Clustering$
analysis$of$the$
3$methods$
 
Figure 2-1 An illustration of qSV analysis. The tool uses discordant read pair, soft 
clipping and split read methods followed by clustering analysis to build evidence that an 
event is real. 
 
To achieve high quality identification of somatic mutations, it is essential for 
genomic variants in the tumours to be manually curated and/or verified experimentally. 
Conventionally, the standard workflow used to verify somatic rearrangements in the 
literatures employs Sanger sequencing. Despite the strength of Sanger sequencing, it 
requires extensive labour input and time to verify a large number of events, especially 
when cleaning up individual PCR products and preparing individual samples for Sanger 
sequencing. Each amplicon needs to be quantified and the sequencing reaction is 
prepared individually as the amount of input DNA depends on the size of the amplicon. In 
this chapter, I present a high throughput workflow, which uses benchtop next generation 
sequencers to verify many events in one experiment.   
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2.2 Results and discussion (Presented as form of manuscript) 
 
Quek et al. 2014. BioTechniques 57:3-38. A workflow to increase verification rate of 
chromosomal structural rearrangements using high throughput next generation 
sequencing (Quek et al., 2014).  
 
 Essentially, a high throughput workflow utilizing pooling strategy of amplicons 
combined with benchtop sequencing and standard bioinformatics techniques was 
established to increase the efficiency of somatic rearrangements verification. The 
proposed workflow facilitates the verification at base resolution of hundreds of breakpoints 
in a single experiment. The workflow was essential for tuning/developing the upstream 
analysis carried out by QCMG sequencing and bioinformatics team. We compared 
sequences and breakpoints of verified somatic rearrangements between the conventional 
and high throughput workflow. The results showed that next generation sequencing 
methods are comparable to conventional Sanger sequencing. The identified breakpoints 
obtained from next generation sequencing methods were highly accurate and 
reproducible. Furthermore, the proposed workflow allows hundreds of events to be 
processed in a shorter time frame compared to the conventional workflow.   
 
 
All figures and supplementary data presented in this chapter include 
 
Figure 2-2 Conventional and high throughput workflows for the verification of somatic 
rearrangements and identification of breakpoints. 
 
Figure 2-3 Verification of somatic structural rearrangements from a highly rearranged 
cancer genome. 
 
Figure 2-4 The ability of different sequencing approaches to resolve the sequence of the 
breakpoints. 
 
Table 2-1 Summary of primers designed and verification rate for pancreatic cancer 
genome using qAmplicon and PCR analysis. 
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Supplementary Figure 2-1 PCR verification of candidate somatic rearrangements using 
short amplicon primers. 
 
Supplementary Figure 2-2 Classification of PCR verification of candidate somatic 
rearrangements.  
 
Supplementary Figure 2-3 Breakdown of verification results for 311 candidate somatic 
events by both short and long amplicons. 
 
Supplementary Figure 2-4 An illustration of the gapped alignment of the sequence reads 
taken from an intra-chromosomal rearrangements.  
 
Supplementary Table 2-1 List of structural variants called by qSV, validated by PCR and 
re-sequencing. (Data can be downloaded from http://goo.gl/5Le9KQ) 
 
Supplementary Table 2-2 Summary of events and verification rates for pancreatic cancer 
genome using HiSeq. (Data can be downloaded from http://goo.gl/5Le9KQ) 
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2.3 Supplementary material 
 
 
 
 
Supplementary Figure 2-1 PCR verification of candidate somatic rearrangements 
using short amplicon primers. This is an example of a gel image of four different event 
types. 
 52 | P a g e 
 
Somatic 
(Positive) Germline Negative 
    
 
Supplementary Figure 2-2 Classification of PCR verification of candidate somatic 
rearrangements. The 3 categories obtained after gel electrophoresis of the PCR product 
spanning the breakpoints of rearrangements in 2% agarose gel are classified as: Somatic 
(positive) - PCR reactions yield a single, clear PCR band in tumour DNA (TD) with no 
matching band in the normal DNA (ND); Germline - both tumour and normal yield PCR 
bands of the expected size; Negative – PCR did not yield any band or PCR yields multiple 
bands; PCR reaction are inconclusive as primers might not specific to the events or the 
failure of PCR reactions.   
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Supplementary Figure 2-3 Breakdown of verification results for 311 candidate 
somatic events tested by both short and long amplicons. In  total 249 events showed 
the same verification results when tested by short or long amplicons. The remaining 62 
events tested both long and short amplicon primers yielded different results (short 
amplicons = 34+10+18; long amplicons = 8+12+42).  
 
*Note: A negative result may not indicate that the event was not verified. The 18 
events called negative in short amplicons category, 8 were somatic and 10 were germline 
in the other category. Similar for the 42 negative events in the long amplicons category, 32 
were somatic and 10 were germline in short amplicons category.   
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Alignment of MiSeq and Sanger sequence 
MiSeq 
Sanger 
...ACTCACCACAACAGAGCAAGCAAAACTCCTTGCAAAGTTTTT... 
...ACTCACCACAACAGAGCAAGCAAAACTCCTTGCAAAGTTTTT... 
Alignment of PGM and Sanger sequence
PGM 
Sanger 
...ACTCACCACAACAGAGCAAGCAAAACTCCTTGCAAAGTTTT-GCAGGTCTCTCA
...ACTCACCACAACAGAGCAAGCAAAACTCCTTGCAAAGTTTTTGCAGGTCTCTCA
PGM 
Sanger 
PGM 
Sanger 
GTTTT-GTTTTGTTTT-GTTTT-GTTTTGAGATGGAGTCTTGCTCTGTCGCCCAGGCCAA
GTTTTTGTTTTGTTTTTGTTTTTGTTTTGAGATGGAGTCTTGCTCTGTCGCCCAGGCCAA
AGTGCAGAGGTGCGATCTCGGCTCACTGC
AGTGCAGAGGTGCGATCTCGGCTCACTGC
(b)
(a) ƐƐĞŵďůĞĚĐŽŶƟŐƐĞƋƵĞŶĐĞƐ
PGM
AACCCAGGAC CAACCTCCAA TGCACAGGCT CTTGACTGCA GGGCAAAGGA  50 
GGTTGACAGT TTTAGTCCCA ATGAATCATG CAACACTTGG GACCTAACTG  100 
GCCGATGCTG GACCTAACCT GCAAATGCTA GAAAACTCAC CACAACAGAG  150 
CAAGCAAAAC TCCTTGCAAA GTTTTGCAGG TCTCTCAGTT TTGTTTTGTT  200 
TTGTTTTGTT TTGAGATGGA GTCTTGCTCT GTCGCCCAGG CCAAAGTGCA  250 
GAGGTGCGAT CTCGGCTCAC TGCAATCTCT GCCTCCCAGG TTCGAGCAAT  300 
TCTCCTGCCT CAGCCTCCCG AGTAGCTGGG ATTACAGGCA CGAATCACCA  350 
CACCTGGCTT A
Sanger
TGAATCATGC AACACTTGGG ACCTAACTGG CCGATGCTGG ACCTAACCTG  50 
CAAATGCTAG AAAACTCACC ACAACAGAGC AAGCAAAACT CCTTGCAAAG  100 
TTTTTGCAGG TCTCTCAGTT TTTGTTTTGT TTTTGTTTTT GTTTTGAGAT  150 
GGAGTCTTGC TCTGTCGCCC AGGCCAAAGT GCAGAGGTGC GATCTCGGCT  200 
CACTGCAATC TCTGCCTCCC AGGTTCGAGC AATTCTCCTG CCTCAGCCTC  250 
CCGAGTAGCT GGGATTACAG GCACGAATC
MiSeq
ggttCCCAGG ACCAACCTCC AATGCACAGG CTCTTGACTG CAGGGCAAAG  50 
GAGGTTGACA GTTTTAGTCC CAATGAATCA TGCAACACTT GGGACCTAAC  100 
TGGCCGATGC TGGACCTAAC CTGCAAATGC TAGAAAACTC ACCACAACAG  150 
AGCAAGCAAA ACTCCTTGCA AAGTTTTTGC AGGTCTCTCA GTTTTTGTTT  200 
TGTTTTTGCT TTTGTTTTGA GATGGAGTCT TGCTCTGTCG CCCAGGCCAA  250 
AGTGCAGAGG TGCGATCTCG GCTCACTGCA ATCTCTGCCT CCCAGGTTCG  300 
AGCAATTCTC CTGCCTCAGC CTCCCGAGTA GCTGGGATTA CAGGCACGCA  350 
 
 
Supplementary Figure 2-4 An illustration of the gapped alignment of the sequencing 
reads taken from an intra-chromosomal rearrangement. (a) Assembled contigs 
sequences obtained from Sanger, MiSeq and PGM sequencing. The nucleotides 
highlighted in green and red denote the breakpoints of the rearranged DNA fragments. 
Nucleotides in black indicate non-templated sequences insertion. The underlined 
nucleotides mark the stretches of Ts called by the three sequencing methods. (b) The 
alignment of assembled contigs was compared to Sanger sequences. In this example, the 
breakpoint identified by MiSeq and Sanger sequencing was at chr17:70371942-70425723 
with T nucleotide insertion. While the breakpoint identified by PGM was at 
chr17:70371950-70425723 with TTGCAAAG nucleotides insertion. 
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3 Chapter 3 
 
Characteristics of somatic breakpoints may indicate repair 
mechanisms that were active or absent during the generation 
of genomic rearrangements  
 
3.1 Introduction 
Structural rearrangements are large genetic events in the genome, which may have 
significant impact on genotypic and phenotypic modifications of tumour cells. The recent 
advancement of sequencing technologies allows us to identify a large range of somatic 
rearrangements to base pair resolution.   
 
In the previous chapter, I established a high throughput workflow to rapidly verify 
somatic rearrangements and confirmed that the qSV tool was able to detect the exact 
location of breakpoints and accurately identify the DNA sequence at each breakpoint 
junction. In this current chapter, I have conducted a detailed analysis of the rearrangement 
breakpoints obtained from whole genome sequencing data of 120 primary pancreatic 
primary tumours. This analysis is able to inform the processes which may have occurred 
during the formation of the breakpoints. Such process may include the defective DNA 
repair mechanisms and may represent candidate targets for therapy.  
 
Double-stranded DNA repair  
In general, there are two main DNA repair mechanisms that cope with double-stranded 
DNA breaks (DBS): homology-dependent and homology-independent mechanisms. 
Defects in these mechanisms are known to be involved in the formation of somatic 
rearrangements. 
 
The homology-dependent mechanism (also known as homologous recombination, 
HR) is a DNA repair process that uses extensive sequence identity between DNA 
fragments. This identity generally extends 100 – 200 bp  (Chen, 2001) and allows for the 
accurate repair of DSB during cell cycle. HR is regulated by a number of genes and the 
BRCA1 and BRCA 2 genes are recognized as key players in the HR pathway (Ishioka et 
al., 1997). 
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Furthermore, the BRCA1/2 genes are also associated with genomic instability in 
cancer, as the inactivation of BRCA1/2 leads to an increase in number of large structural 
rearrangements, which are at least 10 Mb in size (Popova et al., 2012).  
 
Homology-independent mechanism, also termed non-homologous end joining 
(NHEJ), is an alternate DNA repair mechanism, which re-joins the broken ends of DNA 
either without the need of any sequence homology (0 bp; ‘accurate’ NHEJ) or with 
microhomology (in the range of 1 – 25 bp) (Chen, 2001). There are two sub-pathways that 
utilise microhomology, they are ‘error-prone’ NHEJ and microhomology-mediated end 
joining (MMEJ).  
 
‘Error prone’ NHEJ uses short microhomology (1 to 5 bp) present at single stranded 
overhang of the DNA break to facilitate repair. Whilst in MMEJ, the end joining event 
reveals microhomology of 6 to 25 bp to guide the restoration of the break (Chen, 2001). 
Recent cancer studies have shown that the use of microhomology to facilitate repair of 
DNA break is highly prevalent in human cancers (Campbell et al., 2008; Hillmer et al., 
2011; Ng et al., 2012; Stephens et al., 2009).  
 
Mobile DNA elements at rearrangement breakpoints  
In addition to the defective DNA repair pathways, other mechanisms may result in 
structural rearrangements. Mobile elements are abundant in human genome and account 
for approximately 20% of germline structural rearrangements among individuals (Kidd et 
al., 2010; Xing et al., 2009). Mobile elements can replicate and move within the genome. 
These elements can replicate through RNA intermediates or “cut-and-paste” mechanism 
(Finnegan, 1989). Mobile elements can be broadly divided into 2 classes: 
retrotransposons and DNA transposons. Retrotransposons produce RNA transcripts, 
which reverse transcribe into DNA sequences and then insert into a target site. In contrast, 
DNA transposons rely on human transposase enzymes to cut on the target site and then 
move from one to another region in genome. 
 
 In tumours, it has been shown that there is a high density of mobile elements at 
some tumour specific breakpoints and these may facilitate cancer-inducing structural 
rearrangements such as deletions, duplications or translocations (Mauillon et al., 1996; 
Montagna et al., 1999; Rowe et al., 1995; Strout et al., 1998). Given their nature, the 
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activity of transposable elements is mostly suppressed by epigenetic mechanisms at 
transcriptional and post-transcriptional levels (Slotkin and Martienssen, 2007; Yang and 
Kazazian, 2006). However, in the context of disease, particularly in cancer (such as 
colorectal, prostate, breast and ovarian) (Debniak et al., 2001; Depil et al., 2002; Lee et al., 
2012; Montagna et al., 1999; Solyom et al., 2012), it has been shown that the activity of 
transposable elements is frequently elevated. This suggests that the suppression 
mechanisms have been disrupted allowing the transposable elements to regain the 
mobility and may generate new genotypic and phenotypic modifications in the genome. 
Presently, it is uncertain whether these mobile elements are initiators of tumours 
development or are activated later.   
 
Structural rearrangements in pancreatic cancer 
Recent work from our laboratory demonstrated that the pattern of somatic rearrangements 
is able to classify tumours into different genome subtypes with potential clinical relevance 
(Waddell et al., 2015). The pancreatic cancer tumours were classified as follows:  
 
• Stable – tumours with low number of somatic rearrangements distributed across the 
genome (<50 events) 
• Scattered – tumours contain a modest number events (50-200 events) 
• Focal – tumours whereby >50% events occur on a single chromosome  
• Unstable – tumours harbour more than 200 events across the entire genome 
 
 The unstable subtype was associated with somatic BRCA2 or germline BRCA2 and 
PALB2 mutations. Furthermore, the unstable phenotype was suggested as a candidate 
biomarker of therapeutic responsiveness to certain platinum-based chemotherapies which 
generate DNA breaks, as it was hypothesised that these tumours have a defective HR 
pathway. Tumours with a defective HR pathway have been shown to be sensitive to 
platinum-based therapies or PARP inhibitors (Farmer et al., 2005), thus the identification of 
which tumours harbour a defective HR pathway is clinically important. However, the 
unstable subtype or BRCA mutation alone was not able to predict a defective HR pathway 
with 100% accuracy as some tumours which were genomically unstable, did not have a 
BRCA signature or BRCA mutation which suggests other mechanisms are driving the 
instability in these cases. While some tumours with no mutation in BRCA genes or other 
members of HR pathway contained a high BRCA signature or defective HR. Furthermore, 
in some instances, there may be a BRCA mutation which is of unknown function or clinical 
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significance, therefore it is unclear whether the tumours are likely to have a defective HR 
pathway and thus respond to therapy. As the breakpoint characteristics may reflect the 
types of DNA repair which are occurring, in this chapter, I tested whether the 
characteristics at breakpoints may indicate which tumour have a defective BRCA pathway 
in pancreatic cancer. The analysis of breakpoint characteristics also included two other 
cancers types (i.e. oesophageal and ovarian cancers) to further understand the pattern of 
somatic breakpoints characteristics in tumours with defective HR. 
 
 Apart from studying the breakpoints, I analysed the DNA sequences surrounding 
the rearrangements to identify DNA sequence enrichment (i.e. motif) associated with the 
breakpoints. Many of the somatic rearrangements breakpoints displayed strong 
enrichment of A+Ts suggesting that retrotransposition activity and/or common fragile sites 
may implicate in pancreatic tumorigenesis.  
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3.2 Material and Methods 
This chapter utilised whole genome sequence data, which was generated as part of the 
pancreatic and ovarian ICGC projects. The data was sequenced, mapped and qSV tool 
was run to identify all structural rearrangements present in each tumour. This work was 
performed by members of the ICGC pancreatic team. I then used the output of qSV to 
carry out the analysis. The breakpoint sequences were obtained by qSV from the contigs 
assembled from abnormally mapped soft clipped and unmapped reads around potential 
breakpoints. I classified each breakpoint in to 5 different phenotypes (blunt end, 
microhomology, non-templated insertion, genomic shard and free DNA with repeat 
annotation) (Figure 3-1). To understand more about the mechanisms of DNA damage 
repair, the proportion of each breakpoint characteristic and the actual sequence 
surrounding the breakpoints was analysed across the patient cohort. An outline of the 
experimental workflow is shown in Figure 3-2.  
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Figure 3-1 Characteristics of rearrangements breakpoints. The breakpoints are 
characterised into 5 different types: blunt end - a clean break whereby the broken 
chromosome ends are re-joined accurately, microhomology - the presence of terminal 
short overlapping bases between the two repaired chromosome ends, non-templated 
sequence insertion - inserted sequences of free DNA found at the junction of breakpoints, 
genomic shard - inserted free DNA that mapped uniquely to the reference genome near 
the vicinity of the breakage or elsewhere in the genome and free DNA with repeat 
annotation - inserted free DNA that overlapped the sequence of mobile elements. 
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Figure 3-2 Overview framework to analysis the characteristics of somatic 
rearrangements breakpoints. Whole genome sequencing data of 120 primary tumours 
and their matched normal DNA were analysed by the ICGC team using the qSV tool to 
detect potential somatic rearrangements. The somatic rearrangements were categorized 
into the different event types including inversions, amplified inversions, foldback inversions, 
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deletions, translocations, duplications, tandem duplications, and intra-chromosomal 
rearrangements. Downstream analysis of assembled contigs at the breakpoints allows the 
characterization of the breakpoints junctions into 5 phenotypes: blunt end, microhomology, 
non-templated insertion, genomic shard and free DNA with repeat annotation. The length 
of homology at the breakpoints was used to identify potential active repair mechanisms in 
cancers. The DNA sequences surrounding the breakpoint junctions from the reference 
genome were used to identify DNA enriched sequence motifs.   
 
3.2.1 Sample, library preparation and sequencing 
Pancreatic ductal adenocarcinoma and matching normal tissue were obtained from the 
Australian Pancreatic Cancer Genome Initiative (APGI). DNA was extracted using the 
Allprep DNA and RNA Qiagen Allprep® Kit in accordance with the manufacturer’s 
instructions (Qiagen). Paired end library for each sample was constructed according to 
TruSeq® DNA LT Sample Prep Kit v2. In brief, 1 µg genomic DNA was fragmented into 
approximately 300 bp using the Covaris™ S2 sonicator. The fragmented DNA were 
prepared into libraries using the standard illumina© library preparation workflow. The 
fragments DNA were end-repaired, added a 3’-A overhang and ligated with indexed 
adapter. The adapter ligated fragments were size selected with two rounds of SPRI beads 
purification (AxyPrep™Mag PCR Clean-up) using a final bead to DNA volume ratio of 
0.60:1 followed by 0.70:1. An average size of 500 bp molecules were selected and then 
amplified with a total of 8 cycles of PCR to generate constructs compatible for 2 x 101 bp 
HiSeq sequencing. Note: Sequencing was performed by QCMG sequencing team.  
 
3.2.2 Data pre-processing 
Sequence data was aligned to a reference human genome based on the Genome 
Reference Consortium GRCh37 assembly using BWA (Li and Durbin, 2009). The 
alignments were converted to the sequence alignment/mapping (SAM) format and then 
compressed into binary file (BAM) using Samtools (Li et al., 2009). Sorted BAM files were 
merged into a single BAM for each tumour and normal sample. PCR duplicates were 
marked using PiCard MarkDuplicates http://picard.sourceforge.net. The alignment 
summary statistics such as coverage estimation for the merged BAM files were carried out 
by in-house tools. These tools are available for download at 
http://sourceforge.net/projects/adamajava. Note: Data pre-processing were performed 
by QCMG bioinformatics team.  
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3.2.3 Identification of potential somatic rearrangements and breakpoints 
All potential somatic rearrangements were identified using qSV 
(http://sourceforge.net/projects/adamajava). qSV provides three lines of evidence to call 
potential somatic structural rearrangements – clusters of discordant mapped read pairs, 
soft clipping and a split contig alignment generated from de novo assembly of unmapped 
and aberrantly mapped reads. All high confidence events were used in downstream 
analysis and are defined by the following criteria:  
 
• The presence of multiple lines of evidence (discordant pairs, soft clipping on both 
ends and split reads) 
• The presence of two lines of evidence: discordant pairs on both breakpoints and 
soft clipping; discordant pairs on both breakpoints and split reads; or soft clipping on 
both ends and split reads 
• Clustering of 10 or more reads with the same characteristic was used as a cut-off to 
support a potential event.  
 
3.2.4 Verification of potential somatic rearrangements and breakpoints 
Verification of events by SOLiD next generation sequencing was performed by QCMG 
sequencing team. Essentially, 823 of 1,379 events from 22 of the tumours were cross-
validated by SOLiD long mate pair sequencing. In brief, 5 µg genomic DNA was sheared 
into ~2 kb fragments (Covaris®S220), circularized with linker sequences, and followed by 
digestion of the circularized DNA to generate a template used in emulsion PCR. The 
template was flanked with adaptor sequences, coupled to beads and clonally amplified 
before immobilizing to a solid surface for 50 bp sequencing run using the SOLiD v4 (Life 
Technologies). Sequence data was mapped to a reference genome based on the Genome 
Reference Consortium (http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/human/) 
GRCh37 assembly using Bioscope v1.2.1 software suite (Applied Biosystems). Each 
sample was sequenced to an average depth of 199x (ranging from 64 to 333) in the 
tumour, and 195x (ranging from 52 to 308) in the normal.  
 
An additional 64 somatic rearrangements breakpoints from three tumours were 
verified using amplicon deep sequencing as previously described in Chapter 2 (Quek et al., 
2014). In brief, the verification workflow of breakpoints combines the pooling strategy of 
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amplicons with benchtop sequencing and standard bioinformatics techniques such as 
batch primer design, de novo assembly of sequencing data, and automated BLAT to 
confirm the breakpoints of the somatic rearrangements.  
 
3.2.5 Characterization of breakpoint junctions 
In order to characterise the breakpoint junctions, the length of homology at breakpoints 
were calculated based on split contig alignment sequence. The qSV output includes the 
sequence of any microhomology (overlapping) regions at each breakpoint, it also outputs 
non-templated sequence, which does not align to the breakpoint junction. The sequences 
identified as non-templated sequences were analysed using BLAT and then further 
annotated as genomic shard (DNA fragment which maps elsewhere in the genome) and 
free DNA with repeat annotation. The following paragraphs described the characteristics of 
breakpoints junction in more details:  
 
• Blunt end: Throughout this chapter, “0 bp” represents the blunt end characteristic 
as there is zero overlapping bases homology at the break. It describes a clean 
break whereby the broken chromosome ends are re-joined accurately. 
 
• Microhomology: This characteristic is presented as “1 to 5 bp” and “6 or + bp” 
depending on the length of sequence homology at the breakpoint. It describes the 
presence of terminal short overlapping bases between the two repaired 
chromosome ends (Chen, 2001). Microhomology length of 1 to 5 bp is the most 
common feature of NHEJ while length 6 to 25 bp is a feature of MMEJ DNA repair 
mechanism.  
 
• Insertion of non-templated sequence: This characteristic is presented as “-25+ to -1 
bp”. It describes inserted sequence of free DNA found at the junction of breakpoints. 
The length of non-templated sequences ranged from approximately 1 to 150 bp 
based on previous studies on breast and lung cancers (Bignell et al., 2007; 
Stephens et al., 2009). The non-templated sequence was either poorly or not 
aligned with reference genomes. The alignment was performed using BLAT to 
match sequences ≥ 20 bp against human reference genome hg19, USCS 
database. Such sequence could be generated by enzymatic process during DNA 
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repair (Stephens et al., 2009) or due to physical shearing of the chromosomes 
(Bignell et al., 2007).  
 
• Genomic shard: The label of “-25+ to -1 bp” includes the genomic shard 
characteristic. For non-templated sequence that was mapped uniquely to the 
reference genome near the vicinity of the breakage or elsewhere in the genome are 
classified as genomic shard. Typically, the length of genomic shard is approximately 
20 to 500 bp (Bignell et al., 2007; Campbell et al., 2008). It has been proposed that 
complex rearrangements involving multiple breakpoints are associated with 
genomic shards (Hastings et al., 2009). This could be the result of complex 
rearrangements produced by shattering of chromosomal regions followed by 
reassembly (chromothripsis) which may result in some large-scale rearrangements 
containing additional small fragments (genomic shards) inserted at breakpoint 
(Bignell et al., 2007; Stephens et al., 2011). 
 
• Free DNA with repeat annotation: The label of “-25+ to -1 bp” also denotes the 
characteristic of free DNA with repeat annotation. This characteristic describes non-
templated sequence that has overlapped with the sequence of mobile elements. 
 
3.2.6 Analysis of breakpoints characteristics 
After the characterization of breakpoints, statistical tests were conducted to evaluate if the  
patterns of breakpoints characteristics were different between various molecular events. 
These include genome subtype, BRCA mutational signature and BRCA mutation. The 
mutational signatures are calculated based on the context that somatic mutation occur 
using the 96 possible combination of bases at 5’ and 3’ of the mutated base (e.g. C>A, 
C>G, C>T, T>A, T>C, T>G) across the entire genome (Alexandrov et al., 2013). Statistical 
tests were performed using the length of homology at the breakpoint junctions of the 
rearrangements. The statistical tests include (1) unsupervised PCA to search for potential 
clustering in the analysed dataset and (2) Wilcoxon rank sum test to assess the 
differences and relationship between various molecular events and cancer types with 
respect to the categorized length of homology. P<0.05 indicates significant result. Tests 
were performed using Prism and R software (www.r-project.org).  
 
 65 | P a g e 
3.2.7 Motif discovery 
The MEME motif finder was originally developed to discover sequence motifs such as 
DNA binding sites and protein interaction domains (Bailey et al., 2009). Here, it was used 
to find statistically enriched DNA sequence (motifs) surrounding the breakpoint junctions 
and generate position weight matrices. Two hundred base pairs on either side of the 
breakpoints were grouped into their respective analysed subsets. Two sequences of 400 
bp per rearrangement were used as input for MEME and the default short motif width was 
set between 5 bp and 8 bp.  
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3.3 Results  
3.3.1 Structural rearrangements in 120 pancreatic primary tumours 
Whole genome sequencing enabled us to identify a total of 10,074 high confidence 
somatic rearrangements from the 120 pancreatic primary tumours with a median of 83 
rearrangements per tumour (ranging from 11 to 576) (Figure 3-3). Of 1,379 somatic 
rearrangements identified from 22 tumours, 59.7% (823) were cross-validated using 
SOLiD LMP sequencing. An additional 64 rearrangements were also randomly selected 
from patients APGI 1959, APGI 2049 and APGI 2156 for amplicon deep sequencing. 
Using the workflow developed in Chapter 2, 73.4% (47 of 64) rearrangements were 
confirmed as somatic by PCR and 70.2% (33 of 47) had their exact breakpoint location 
identified by aligning MiSeq sequencing results to the human reference genome 
(Supplementary Table 3-1).  
 
The frequency of different types of somatic rearrangements varied among 
individuals across the cohort. The somatic rearrangements were classified as intra-
chromosomal (events within a single chromosome) or inter-chromosomal (events between 
two different chromosomes, i.e. translocations). The proportion of intra-chromosomal 
rearrangements in this dataset was 87.8% (8,847 of 10,074) and inter-chromosomal 
rearrangements was 12.2% (1,227 of 10,074) highlighting that intra-chromosomal 
rearrangements generally prevail in pancreatic tumours. This is consistent to what have 
been described for 13 previously characterised pancreatic tumours (Campbell et al., 2010) 
and is also similar to other cancer types including colorectal, breast and liver (Kloosterman 
et al., 2011; Stephens et al., 2009; Totoki et al., 2011). The orientation of the read pairs 
and the association of copy number change enables intra-chromosomal events to be 
further classified as inversions, amplified inversions, foldback inversions, deletions, 
duplications or tandem duplications. Events that are not associated with an inversion or a 
copy number change were broadly grouped as other intra-chromosomal rearrangements. 
The distribution of somatic rearrangements was as follows: 14.7% (1,481) inversions, 
4.2% (426) amplified inversions, 6.4% (647) foldback inversions, 12.8% (1,291) deletions, 
12.2% (1,227) translocations, 1.3% (130) duplications, 1.7% (175) tandem duplications, 
46.6% (4,697) other intra-chromosomal rearrangements (Figure 3-3). Inversions formed 
the most common sub-classification, which is in contrast to primary breast cancer 
genomes, whereby tandem duplications are the most common sub-classification 
(Stephens et al., 2009). 
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Figure 3-3 Spectrum of somatic rearrangements and different types across 120 
pancreatic primary tumours. Patients are presented on the x-axis and the number of 
each rearrangement types is on the y-axis. Rearrangements are coloured according to the 
event types as shown in the legend. Dashed line indicates the median of rearrangements 
per tumour. 
 
3.3.2 Characterisation of breakpoints  
The formation of somatic rearrangements in cancer genomes may rely on sequence 
homology dependent and/or independent mechanisms (Chen, 2001; Korbel et al., 2007; 
Lam et al., 2010). Here, I characterised the breakpoints junctions as blunt end, 
microhomology, non-templated insertion, genomic shard or free DNA with repeat 
annotation. Of the 10,074 high confidence somatic rearrangements, a total of 9,741 
contained split contig alignment, which allowed the prediction of the sequence context at 
the rearrangements junction to facilitate the characterization of breakpoint phenotypes 
(Figure 3-3). The proportion of these breakpoints characteristics within the pancreatic 
cohort are shown in Figure 3-4  and were characterised as: 
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 Blunt end: Of 9,741 somatic rearrangements, 1,207 (12.4%) were blunt end with an 
average of 10 rearrangements per patient (ranging from 0 to 56). Two of the 120 patients 
did not display blunt end characteristics (APGI 2598 and APGI 3513). 
 
 Microhomology: In this dataset, the vast majority of the rearrangements shared 
short stretches of overlapping bases. A total of 7,283 (74.8%) rearrangements displayed 
microhomology with an average of 61 rearrangements per patient (ranging from 7 to 448). 
No long homologous sequences (>100 bp) were observed in this dataset (the longest 
homology sequence seen was 17 bp long).  
 
 Insertion of non-templated sequences: Of 9,741 rearrangements, 1,251 (12.8%) 
displayed insertion of free DNA at the breakpoint junctions. Of these, 1,160 (12.0%) 
displayed non-templated sequence insertion characteristic at the breakpoints junctions 
with an average length of 6.4 bp (ranging from 1 to 68 bp) (Figure 3-4). These non-
templated sequences were either poorly or not aligned with reference genomes.  
 
 Genomic shard: Thirty-nine (0.4%) of the rearrangements were classified as 
genomic shard with an average length of 34.2 bp (ranging from 20 to 76 bp). Genomic 
shards were quite uncommon and observed in 29 of 120 pancreatic tumours.  
 
 Free DNA with repeat annotation: Fifty-two (0.5%) rearrangements had free DNA 
situated along mobile elements such as LINEs, SINEs, LTR retrotransposons and DNA 
repeats. The average length of these free DNA was 34.0 bp (ranging from 20 to 71 bp) 
and this characteristic was observed in 37 of 120 pancreatic tumours.  
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Figure 3-4 Proportion of breakpoints characteristics across 120 pancreatic primary 
tumours. Patients are on the x-axis and the percentage of the breakpoints characteristics 
for each rearrangement within each tumour is on y-axis.  
In summary, these characteristics of breakpoints (i.e. sequence homology or 
sequence insertion) may represent “scars” in the cancer genome displaying their history. 
The estimated contributions of breakpoint characteristics are consistent to what have been 
reported in previous studies with microhomology being the largest contributor of all 
characteristics (Ng et al., 2012; Stephens et al., 2011) (Table 3-1).  
 
Table 3-1 Characteristics of somatic rearrangements breakpoints 
Type of 
characteristics 
Estimated 
contribution 
(n=120) 
Contribution 
reported by Ng 
et al, 2012  
(n= 2) 
Contribution 
reported by 
Stephens et al, 
2011 (n = 11) 
Possible 
mechanism(s) 
associated with 
somatic 
rearrangements 
formation 
Blunt ends (0 bp) 12.4% 16.0% 23.1% ‘accurate’ NHEJ 
Microhomology  74.8% 68.0% 56.5% ‘error-prone’ 
NHEJ, MMEJ 
Non-templated 
sequence (<20 
bp) 
12.0% 16.0% 13.2% ‘error-prone’  
NHEJ 
Genomic shard 
(insertion of non-
templated 
sequence (>20 
bp) 
~0.4% 0% 7.2% ‘error-prone’  
NHEJ, 
chromothripsis 
Mobile element 
(≥20 bp) 
~0.5% - - Retrotransposition  
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3.3.3 Microhomology of somatic rearrangements 
According to the literature, the different lengths of short overlapping bases at breakpoints 
reveals the involvement of non-homologous recombination mechanism, which is also 
known to have two sub-pathways: (1) non-homologous end joining (NHEJ) which uses 1-5 
bp microhomology and (2) microhomology-mediated end joining (MMEJ) uses >5 bp 
microhomology (Chen, 2001; Hastings et al., 2009). 
 
Of 9,741, 6,525 (67.0%) rearrangements contained microhomology of 1-5 bp 
suggesting that NHEJ is more frequent in pancreatic cancer genomes while the 
prevalence of MMEJ is approximately 7.8% (758 rearrangements had >5 bp 
microhomology) (Figure 3-5). Overall, the rearrangement breakpoints showed an average 
length of 3.0 bp microhomology (ranging from 1 to 17 bp). When comparing to the somatic 
rearrangements detected in 95 tumours (such as breast, head and neck, colorectal, 
prostate carcinomas, melanoma, multiple myeloma, and chronic lymphocytic leukaemia) 
(Drier et al., 2013), our cohort of pancreatic cancer genomes has longer microhomology 
length at breakpoints junctions (average of 3.0 bp vs. 1.7 bp). This suggests that the 
efficiency of DNA repair in our pancreatic cohort might be higher than the cohort studied 
by Drier et al. as the efficiency of DNA repair has been shown to increase as the length of 
homology increases (Villarreal et al., 2012).  
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Figure 3-5 Breakpoint characteristics across 120 pancreatic primary tumours. 
Microhomology in bp are shown for each breakpoints as a positive number. Patients on 
the x-axis are ordered by the number of somatic rearrangements (y-axis). Blunt end has 
homology of 0 bp. Non-templated sequences (insertion of free DNA) are shown as 
negative numbers.   
 
 Drier et al. reported that the distribution of microhomology lengths varied by the 
type of rearrangement across the 95 tumours (Drier et al., 2013). To determine if different 
event types (deletions, inversions, duplications, translocations and intra-chromosomal 
rearrangements) show different breakpoint characteristics and thus potentially are repaired 
differently in pancreatic cancer, the distribution of microhomology lengths for each type 
was analysed. (Figure 3-6). In our dataset, the distributions of microhomology length are 
indeed varied by different event types which agree with what was reported in Drier et al. 
(Drier et al., 2013). It was observed that microhomology of 1 or 2 bp is the most common 
overlapped sequence across majority of the event types (Figure 3-6). This agrees with the 
observations in breast cancers, where most of the rearrangement types had distinctive 
distribution with 2 bp except in amplification, which blunt end (0 bp) was the most common 
(Stephens et al., 2009).  
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Figure 3-6 Distribution of microhomology length of somatic breakpoints by event 
type across 120 pancreatic tumours. The number of somatic rearrangements is plotted 
against the number of base pairs of microhomologies. The length of microhomologies is 
presented on the x-axis and the number of rearrangements is on the y-axis.  
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3.3.4 Characteristics of breakpoints in cancer genomes 
Members of ICGC Australia pancreatic team recently grouped pancreatic tumours (PDAC) 
into 4 subtypes termed stable, scattered, focal and unstable (Figure 3-7) (Biankin et al., 
2012). The unstable tumours were found to be associated with genome instability and 
contained a large number of rearrangements. Many, but not all of the unstable tumours 
contained mutations in key DNA damage genes (BRCA1/2, ATM or PALB2) and were 
associated with a high BRCA mutational signature. Patients with an unstable genome also 
responded to platinum-based chemotherapies probably due to the defective HR pathway. 
The identification of which tumours harbour a defective HR pathway is clinically important, 
however, the unstable subtype or BRCA mutation alone is not able to predict a defective 
HR pathway with 100% accuracy. Here, I tested whether breakpoint characteristics in 120 
pancreatic tumours may indicate which tumours have a defective BRCA pathway. Initially, 
the analysis was performed to look for difference in breakpoint characteristics between the 
genomic subtypes, then between BRCA carriers and finally between tumours with high or 
low BRCA signatures. In an attempt to further explore and validate findings, data from 
ovarian (AOCS) and oesophageal cancers (OESO) were incorporated in a cross cancers 
analysis. 
 
3.3.4.1 Breakpoints characteristics in the different genome subtypes of PDAC 
Here, I evaluated if there are differences in breakpoints characteristics across the 4 
genome subtypes that could identify potential mechanisms involved in the formation of 
somatic rearrangements. The cohort of 120 PDAC were grouped as: 32 focal (26.7%), 64 
scattered (53.3%), 15 stable (12.5%), and 9 unstable (7.5%) genome subtypes.  
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Figure 3-7 Classification of PDAC primary tumours based on the genomic profile. A 
representative tumour from each subtype is shown using Circos plots (Krzywinski et al., 
2009). Chromosome ideograms are shown in the outer ring. The inner two rings show the 
copy number profiles obtained by GAP analysis (Genome Alteration Print) (Popova et al., 
2009) and B allele frequency. Within the circle, each line connects the sequenced 
junctions of rearrangements – translocation (dark blue), deletions (green), inversions 
(yellow), tandem duplications (dark red), duplications (red), foldback inversions (light 
orange), amplified inversions (dark orange), and intra-chromosomal (very light blue). The 
numbers and the distribution of somatic rearrangements within a genome were used to 
classify tumours into 4 subtypes (Waddell et al., 2015) 
 
The number of events with different breakpoint characteristics was used in the PCA 
analysis to identify subgroups. PCA suggests that there was difference between the 
unstable and stable group (Figure 3-8). However, this difference might be associated with 
the number of events since the genome subtypes were originally based on the number of 
events in the genome. Breakpoint characteristics were not able to separate tumours within 
focal subtype. This is perhaps due to the peculiar phenotype of the focal subtype where 
most of the breakpoints were localized on a single chromosome and contained features of 
complex rearrangements including chromothripsis and breakage-fusion-bridge. In contrast, 
tumours with the scattered and stable subtypes contained events which are randomly 
distributed through the genome.  
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Figure 3-8 PCA plot of breakpoints across the 4 genome subtypes of PDAC. Each 
bubble represents a pancreatic cancer sample. Samples are coloured according to the 
genome subtypes – focal, orange; scattered, green; stable, blue; unstable, red. Size of the 
bubble corresponds to the number of somatic rearrangements in each sample. (a) PCA 
was applied to all 9,741 somatic rearrangements with measured length of homology for 
120 samples to calculate the variance of the principal components. PCA was plotted in two 
dimensions using their projections onto the first two principle components. (b) The 
samples were labelled with unique patient ID. (c) PCA plot emphasized on focal subtype. 
(d) PCA plot emphasized on scattered subtype. (e) PCA plot emphasized on stable 
subtype. (f) PCA plot emphasized on unstable subtype. 
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 To determine whether the genome subtypes are associated with specific repair 
pathways, the frequency distribution of different length of homology across the 4 genome 
subtypes (i.e. focal, scattered, stable and unstable) was assessed. The unstable subtype 
which was associated with the HR defective pathway, showed a lower frequency of 
breakpoint with blunt end characteristic suggesting that the HR pathway might not be 
intact. A significance difference between scattered and unstable subtypes was observed in 
blunt end characteristic (p=0.0422, Wilcoxon rank-sum test) (Figure 3-9) (Chen, 2001). 
However, the distribution of categorized length of homology between stable and unstable 
subtypes showed no differences suggesting that the difference observed between stable 
and unstable subtypes observed in PCA analysis could be driven by the number of 
rearrangements in a sample as the unstable tumours have a higher number of somatic 
rearrangements. 
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Figure 3-9 Frequency distribution of breakpoints across 4 genome subtypes of 
PDAC. Each genome subtype (x-axis) was plotted against the frequency distribution of 
somatic rearrangements (y-axis). The sample size for each genome subtype was as 
follows: focal (n=32), scattered (n=64), stable (n=15), and unstable (n=9). Boxplots were 
coloured according to the genome subtype – scattered, green; stable, blue; unstable, red. 
(a) The categorized length of homology -25+ to -1 bp denotes the characteristic of free 
DNA insertion at the break. (b) The categorized length of homology 0 bp denotes the 
characteristic of blunt end. (c) and (d) The categorized length of homology 1 to 5 bp and 6 
to 25 bp denote the characteristic of microhomology. All p-values are from Wilcoxon rank-
sum test. Comparisons with p-value >0.05 were not labelled.   
 
3.3.4.2 Breakpoint characteristics  associated with BRCA mutational signature of 
PDAC 
The sequence context of somatic substitutions and indels has been shown to predict the 
likely mutation processes or signatures within the different tumours. Twenty-one 
mutational signatures were initially described from the analysis of 7,042 tumours from 30 
different cancer types (Alexandrov et al., 2013). These mutational signatures were 
associated with biological features or characteristic related to cancer, for example, age, 
smoking APOBEC, BRCA1/2 mutations, DNA MMR deficiency, ultraviolet light, 
immunoglobulin gene hypermutation, Pol ε mutations, and temozolomide. The signatures 
which the authors termed, the “BRCA signature” was associated with inactivating 
mutations of the BRCA1/2 genes. Tumours with BRCA1 and BRCA2 mutations showed a 
large contribution from BRCA mutational signature (reported as signature 3). However, 
some tumours with a substantial contribution from BRCA signature did not have BRCA1 
and BRCA2 mutations, indicating that other mechanisms or genes rather than solely 
BRCA1 and BRCA2 inactivation generate this signature (Alexandrov et al., 2013). 
 
In pancreatic cancer, the presence of mutation in the BRCA1/2 genes and high 
BRCA mutational signature were associated with the unstable subtype of pancreatic 
cancer. However, not all tumours with a high BRCA mutational signature harboured BRCA 
gene mutations and not all unstable tumours contained a high BRCA signature.  
 
 To determine if the BRCA signature was associated with defects in specific DNA 
repair pathways, the differences in breakpoints characteristics of the tumours with a high 
and low contribution of BRCA mutational signature were evaluated. The number of 
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mutation per Mb associated with BRCA mutational signature for 120 pancreatic primary 
tumours ranged from 0.00 to 0.70 (Figure 3-10). To evaluate the breakpoint characteristics, 
the upper quartile (i.e. high contribution of BRCA signature) of the BRCA mutational 
signature was compared to the lower quartile (i.e. low contribution of BRCA signature). 
The value of high BRCA mutational signature ranged from 0.41 to 0.70 and the value of 
low BRCA mutational signature ranged from 0 to 0.14. A total of 14 tumours with a high 
contribution of the BRCA mutational signature and 30 tumours with a low contribution of 
the BRCA signature were compared.  
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Figure 3-10 The number of mutation per Mb that contributed for BRCA mutational 
signature within each PDAC sample. The samples were ranked by prevalence (red 
bars). The green bar marks the cut-off for high and low contribution of BRCA signature.  
 
There was a difference in the characteristics of breakpoints for blunt end (length 0 
bp; p=0.0137, Wilcoxon rank-sum test) and microhomology (length 1 to 5 bp; p=0.0487, 
Wilcoxon rank-sum test) between tumours with a high and low BRCA signature (Figure 3-
11). These results suggest that the two known NHEJ pathways ‘accurate’ and ‘error-prone’ 
(Pfeiffer et al., 2000) might have different frequency of activity in tumours with high and 
low BRCA mutational signature. The ‘accurate’ and ‘error-prone’ NHEJ share different 
elements of HR pathway (Pfeiffer et al., 2000), thus the ‘accurate’ NHEJ is independent of 
homology sequence resulting in blunt end ligation (0 bp) while the ‘error-prone’ NHEJ uses 
microhomology to repair non-complementary ends. The results here suggest that the 
tumours with a high BRCA mutational signature might present a HR deficiency pathway 
with less activity of the ‘accurate’ NHEJ. These BRCA deficiency tumours seem to favour 
the ‘error-prone’ NHEJ pathway that uses microhomology to repair the chromosomal 
breaks.  
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Figure 3-11 Frequency distribution of breakpoints of BRCA mutational signature in 
PDAC samples. The number of mutations per Mb that contributed to the BRCA mutational 
signature was calculated. The samples within the high and low BRCA mutational signature 
cut-off value (x-axis) were plotted against the frequency of somatic rearrangements (y-
axis). The sample size for a high and low BRCA mutational signature was as follows: high 
(n=14) and low (n=30). Boxplots were coloured according to quartiles of BRCA mutational 
signature – high, orange; low, green. (a) The categorized length of homology -25+ to -1 bp 
denotes the characteristic of free DNA insertion at the break. (b) The categorized length of 
homology 0 bp denotes the characteristic of blunt end. (c) and (d) The categorized length 
of homology 1 to 5 bp and 6 to 25 bp denote the characteristic of microhomology. All p-
values are from Wilcoxon rank-sum test. Comparisons with p-value >0.05 were not 
labelled.   
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3.3.4.3 Breakpoint characteristics associated with BRCA mutation of PDAC 
As tumours with a high BRCA mutational signature do not always have BRCA mutations, 
the breakpoint characteristics of tumours that were BRCA mutant and BRCA wild type 
were investigated. A total of 6 tumours with BRCA mutation were compared with 114 
tumours with BRCA wild type. 
 
The frequency distribution of blunt end breakpoints (0 bp) in tumours with BRCA 
mutation was significantly lower as compared to BRCA wild type tumours (p=0.0189, 
Wilcoxon rank-sum test) (Figure 3-12). In agreement with the previous results observed in 
the BRCA mutational signature, here the frequency of breakpoints with categorized length 
of homology 1 to 5 bp was higher in tumours with BRCA mutation than in tumours with 
BRCA wild type. However, the difference was not statistically significant. As there were 
only 6 tumours with BRCA mutation, this analysis might be limited by the sample size.  
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Figure 3-12 Frequency distribution of breakpoints of BRCA gene mutation in PDAC 
samples. BRCA mutation status was plotted against the frequency of somatic 
rearrangements (y-axis). The sample size for each mutation status was as follows: 
BRCA_MT (n=6), and BRCA_WT (n=114). Boxplots were coloured according to BRCA 
gene mutation status – samples with BRCA1/2 mutant (BRCA_MT), orange; samples with 
BRCA1/2 wild type (BRCA_WT), green. (a) The categorized length of homology -25+ to -1 
bp denotes the characteristic of free DNA insertion at the break. (b) The categorized length 
of homology 0 bp denotes the characteristic of blunt end. (c) and (d) The categorized 
length of homology 1 to 5 bp and 6 to 25 bp denote the characteristic of microhomology. 
All p-values are from Wilcoxon rank-sum test. Comparisons with p-value >0.05 were not 
labelled. 
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3.3.4.4 Breakpoint characteristics associated with BRCA mutational signature of 
AOCS 
To verify the association with BRCA mutational signature and breakpoint characteristics, 
data from ovarian cancer was analysed, as the frequency of BRCA gene mutations are 
higher in ovarian cancer genomes. Therefore, in ovarian cancer, I further investigated the 
difference in characteristics of breakpoints for the following: (1) BRCA mutational signature 
and (2) BRCA gene mutation in ovarian cancer, the analysis was conducted in 80 primary 
high-grade serous ovarian cancer genomes.  
 
 The contribution of the BRCA mutational signature in mutation per Mb for ovarian 
cancer genomes ranged from 0.034 to 4.32 (Figure 3-13), which is much higher than 
pancreatic cancer (ranged from 0.00 to 0.70). To evaluate the breakpoint characteristics, 
the upper quartile (i.e. high contribution of BRCA signature) of the BRCA mutational 
signature was then compared to the lower quartile (i.e. low contribution of BRCA 
signature). The value of high BRCA mutational signature ranged from 1.82 to 4.32 and low 
BRCA signature ranged from 0.03 to 0.79. A total of 14 tumours with a high BRCA 
mutational signature were compared with 29 tumours containing a low contribution of the 
BRCA mutational signature. 
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Figure 3-13 The number of mutation per Mb that contributed for BRCA mutational 
signature within each ovarian sample. The samples were ranked by prevalence (red 
bars). The green bar marks the upper quartile (i.e. high) and lower quartile (i.e. low) of 
BRCA mutational signature.  
 
 The frequency distribution of breakpoint characteristics showed a similar trend 
when comparing to the results obtained from pancreatic cancer. Tumours with high BRCA 
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signature had fewer somatic breakpoints displaying blunt end (0 bp) and more somatic 
breakpoints displaying microhomology (1 to 5bp) (p=0.0463, Wilcoxon rank-sum test) 
suggesting again that ‘error-prone’ NHEJ could be more active in HR deficient tumours as 
suggested by Pfeiffer et al. (Pfeiffer et al., 2000) (Figure 3-14). 
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Figure 3-14 Frequency distribution of breakpoints of BRCA mutational signature in 
AOCS samples. The number of mutations per Mb contributed to the BRCA mutational 
signature was calculated. The samples within the high and low BRCA mutational signature 
cut-off value were plotted against the frequency of somatic rearrangements (y-axis). The 
sample size for a high and low BRCA mutational signature was as follows: high (n=14) and 
low (n=29). Boxplots were coloured according to quartiles of BRCA mutational signature – 
high, orange; low, green. (a) The categorized length of homology -25+ to -1 bp denotes 
the characteristic of free DNA insertion at the break. (b) The categorized length of 
homology 0 bp denotes the characteristic of blunt end. (c) and (d) The categorized length 
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of homology 1 to 5 bp and 6 to 25 bp denote the characteristic of microhomology. All p-
values are from Wilcoxon rank-sum test. Comparisons with p-value >0.05 were not 
labelled.   
 
3.3.4.5 Breakpoint characteristics associated with BRCA mutation of AOCS 
A total of 33 ovarian tumours with BRCA mutation were compared to 25 tumours with 
BRCA wild type. However, similar to the BRCA signature, the frequency distribution 
showed that blunt end (0 bp) and microhomology (1 to 5 bp) breakpoints were differed 
between tumours with BRCA mutation and BRCA wild type. Expectedly, the tumours with 
BRCA mutation had higher frequency of microhomology breakpoints compared to BRCA 
wild type tumours while tumours with BRCA wild type had higher frequency of blunt end 
breakpoints (blunt end: p=0.0147, microhomology: p=0.0031, Wilcoxon rank-sum test) 
(Figure 3-15). 
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Figure 3-15 Frequency distribution of breakpoints of BRCA gene mutation in AOCS 
samples. BRCA mutation status was plotted against the frequency of somatic 
rearrangements (y-axis). The sample size for each mutation status was as follows: 
BRCA_MT (n=33) and BRCA_WT (n=25). Boxplots were coloured according to BRCA 
gene mutation status – samples with BRCA mutant (BRCA_MT), orange; samples with 
BRCA wild type (BRCA_WT), green. (a) The categorized length of homology -25+ to -1 bp 
denotes the characteristic of free DNA insertion at the break. (b) The categorized length of 
homology 0 bp denotes the characteristic of blunt end. (c) and (d) The categorized length 
of homology 1 to 5 bp and 6 to 25 bp denote the characteristic of microhomology. All p-
values are from Wilcoxon rank-sum test. Boxplots with p-value >0.05 were not labelled.   
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3.3.4.6 Breakpoint characteristics associated with BRCA gene mutation across 
different tumour types 
To increase the number of tumours with BRCA mutation, samples in PDAC, AOCS and 
OESO datasets were combined. Figure 3-16 shows that the distribution of breakpoints 
characteristics in 40 BRCA mutant (6 PDAC and 33 AOCS and 1 OESO) and 182 BRCA 
wild type tumours (114 PDAC, 47 AOCS and 21 OESO). Consistent with previous sections, 
the frequency of breakpoints with blunt end (0 bp) was higher in tumours with BRCA wild 
type while the frequency of breakpoints with microhomology (1 to 5 bp) was higher in 
tumours with BRCA mutation (blunt end: p=0.0002, microhomology: p<0.0001, Wilcoxon 
rank-sum test). 
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Figure 3-16 Frequency distribution of breakpoints of BRCA gene mutation across 
PDAC, AOCS and OESO samples. BRCA mutation status was plotted against the 
 87 | P a g e 
frequency of somatic rearrangements (y-axis). The sample size for each BRCA mutation 
status was as follows: BRCA_MT (n=40) and BRCA_WT (n=182). Boxplots were coloured 
according to BRCA mutation status – tumours with BRCA mutant (BRCA_MT), orange; 
tumours with BRCA wild type (BRCA_WT), green. (a) The categorized length of homology 
-25+ to -1 bp denotes the characteristic of free DNA insertion at the break. (b) The 
categorized length of homology 0 bp denotes the characteristic of blunt end. (c) and (d) 
The categorized length of homology 1 to 5 bp and 6 to 25 bp denote the characteristic of 
microhomology. All p-values are from Wilcoxon rank-sum test. Comparisons with p-value 
>0.05 were not labelled.  
 
 Although both are members of the HR pathway, studies have shown that BRCA1 
and BRCA2 have distinct function in DNA repair. Therefore, mutations in BRCA1 and 
BRCA2 may result in different effects in cancers (Gudmundsdottir and Ashworth, 2006; Liu 
et al., 2012; Liu and West, 2002). To evaluate if there is difference in breakpoints 
characteristics of tumours with BRCA1 or BRCA2 gene mutations, 19 tumours with 
BRCA1 mutation (1 PDAC and 18 AOCS) and 9 tumours with BRCA2 mutation (5 PDAC, 
3 AOCS and 1 OESO) were investigated. 
 
 Interestingly, when comparing the breakpoint characteristics of somatic 
rearrangements, the result showed that the frequency distribution of microhomology and 
non-templated sequence insertion characteristics were different between tumours with 
BRCA1 and BRCA2 mutation (p=0.0123 and p=0.0083 respectively, Wilcoxon rank-sum 
test) (Figure 3-17). 
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Figure 3-17 Frequency distribution of breakpoints between BRCA1 and BRCA2 
mutation samples across PDAC, AOCS, and OESO samples. BRCA mutation status 
was plotted against the frequency of somatic rearrangements (y-axis). The sample size for 
each mutation status was as followed: BRCA1_MT (n=19) and BRCA2_WT (n=9). 
Boxplots were coloured according to BRCA gene mutation status – samples with BRCA1 
mutant (BRCA1_MT), blue-green; samples with BRCA2 mutant (BRCA2_MT), dark green. 
(a) The categorized length of homology -25+ to -1 bp denotes the characteristic of free 
DNA insertion at the break. (b) The categorized length of homology 0 bp denotes the 
characteristic of blunt end. (c) and (d) The categorized length of homology 1 to 5 bp and 6 
to 25 bp denote the characteristic of microhomology. All p-values are from Wilcoxon rank-
sum test. Comparisons with p-value >0.05 were not labelled.   
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Taken together, the results from different data sets show that the frequency of 
breakpoints with microhomology of 1 to 5 bp was higher and blunt end (0 bp) was lower in 
tumours with either BRCA gene mutation or a high BRCA mutational signature in PDAC 
and AOCS cancer genomes (Table 3-2). These results suggest that ‘error-prone’ NHEJ 
could be an alternative DNA repair mechanism of the somatic rearrangements due to the 
deficiency of BRCA in HR DNA repair mechanism (Patel et al., 2011). Whilst, the 
frequency of breakpoints with a blunt end was higher in tumours with BRCA wild type or a 
low BRCA mutational signature which may indicate that the ‘accurate’ NHEJ shares 
elements with HR pathway (Pfeiffer et al., 2000). 
 
Table 3-2 Summary results of BRCA mutational signature and BRCA mutation 
   Median of the frequency changes across the categorized length of 
homology 
 Difference 
between… -25 to -1 bp 0 bp 1 to 5 bp 6 to 25 bp 
PDAC 
(n=120) 
BRCA mutational 
signature  
high vs. low 
0.155 vs. 0.115 
(p = 0.8077) 
0.09 vs. 0.14 
(p = 0.0137) 
0.68 vs. 0.63 
(p = 0.0487) 
0.085 vs. 0.08 
(p = 0.8165) 
BRCA mutation 
BRCA_MT vs. 
BRCA_WT 
0.16 vs. 0.12 
(p = 0.2306) 
0.09 vs. 0.13 
(p = 0.0189) 
0.67 vs. 0.66 
(p = 0.4697) 
0.09 vs. 0.08 
(p = 0.8669) 
AOCS 
(n=80) 
BRCA mutational 
signature  
high vs. low 
0.125 vs. 0.13 
(p = 0.3028) 
0.1 vs. 0.11 
(p = 0.2009) 
0.685 vs. 0.66 
(p = 0.0463) 
0.09 vs. 0.09 
(p = 0.5568) 
BRCA mutation 
BRCA_MT vs. 
BRCA_WT 
0.11 vs. 0.13 
(p = 0.0826) 
0.1 vs. 0.12 
(p = 0.0147) 
0.7 vs. 0.65 
(p = 0.0031) 
0.085 vs. 0.09 
(p = 0.6149) 
PDAC + 
AOCS + 
OESO  
(n=222) 
BRCA mutation 
BRCA_MT vs. 
BRCA_WT  
0.12 vs. 0.14 
(p = 0.1394) 
0.1 vs. 0.12 
(p = 0.0002) 
0.695 vs. 0.65 
(p <0.0001) 
0.09 vs. 0.09 
(p = 0.8442) 
BRCA mutation 
BRCA1_MT vs. 
BRCA2_MT 
0.11 vs. 0.16 
(p = 0.0083) 
0.1 vs. 0.1 
(p = 0.7503) 
0.7 vs. 0.6 
(p = 0.0123) 
0.08 vs. 0.09 
(p = 0.6566) 
      
 
3.3.5 Pattern of DNA sequence surrounding the breakpoints 
There are many ways a cell acquires DNA breaks. Here, instead of genomic sequence at 
the breakpoints, the sequences surrounding the breaks were analysed. Studies have 
suggested that regions of the genomes such as fragile sites and repeats are prone to 
chromosomal breakage and these regions display certain DNA features (Fungtammasan 
et al., 2012; Lee et al., 2012; Prak and Kazazian, 2000). In this section, 200 bp regions 
flanking each side of the breakpoints were used as input to search for DNA enrich motifs 
using MEME Suite motif finder (Bailey et al., 2009). 
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3.3.5.1 Pattern of DNA sequence among the genome subtypes of PDAC 
A total of 19,482 breakpoints were examined – 4,242 breakpoints from focal subtype 
(n=32), 9,474 from scattered (n=64), 714 from stable (n=15) and 5,052 from unstable 
(n=9).  
 
A total of 92 short motifs were discovered across the four genome subtypes of 
PDAC (Figure 3-18). The top five most frequent motifs in each subtype were manual 
curated for their contribution in other subtypes. Only the motif ‘RAAATA’ was shared 
between focal and stable subtypes at a frequency of 30% and 34% respectively (Table 3-
3). In this case, the consensus DNA pattern of motif ‘RAAATA’ is ‘AAAATA’ with nucleotide 
degeneracy at the 1st position. However, other motifs with A+Ts enrichment were also 
observed in other subtypes (such as ‘ARAGAAA’, ‘RAAATR’, ‘AWATAY’, ‘AAATRY’, 
‘AAANAAAA’, ‘AAATAAW’). This signal of A enrichment was previous reported to be 
involved in chromosomal fragile sites or TE integration sites and showed to generate 
cancer-specific rearrangements (such as translocations and deletions) in human cancers 
(Durkin et al., 2008; Gandhi et al., 2010; Glover and Stein, 1988; Lee et al., 2012). 
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Figure 3-18 Consensus motifs at breakpoint junction in each genome subtype. The 
frequency of the enriched motifs was plotted against the 92 discovered motifs. The graph 
is ordered by the frequency of matching motif patterns in each subtype. Bars are coloured 
according to the genome subtype – focal, orange; scattered, green; stable, blue; unstable, 
red. The abbreviation for the degenerate bases is found in Supplementary Table 3-2. 
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Table 3-3 Comparison of the discovered motifs across genome subtypes of PDAC 
Motifs Focal Stable Scattered Unstable 
CMCAS 55.6% - - - 
RAAATA 30.3% 34.0% - - 
CHGYCTC 12.1% - - - 
ARAGAAA 11.1% - - - 
SAGGCTGR 8.5% - - - 
GAGAHA - 28.3% - - 
AGCCTGG - 5.7% - - 
TGAGCCA - 4.6% - - 
CCTCCCAM - 4.6% - - 
CACRB - - 53.0% - 
RAAATR - - 45.5% - 
SAGAAW - - 26.0% - 
AWATAY - - 16.7% - 
CCMGSC - - 13.8% - 
AAATRY - - - 38.7% 
AGSCDGG - - - 14.9% 
AAANAAAA - - - 14.3% 
AAATAAW - - - 9.6% 
RGAGAAA - - - 7.3% 
 
 
3.3.5.2 Pattern of DNA sequence surrounding the breakpoints of event types 
The involvement of chromosomal fragile sites or TE integration sites has been shown to 
generate cancer-specific rearrangement (such as translocations and deletions) in human 
cancers (Dillon et al., 2010; Gandhi et al., 2010; Lee et al., 2012; Popescu, 2003). Here, I 
conducted analysis of DNA motifs to evaluate if there is a preferred DNA sequences at the 
surrounding regions of the breakpoints across various event types (i.e. deletions; 
inversions - comprised of inversions, foldback inversions and amplified inversions; 
duplications - comprised of duplications and tandem duplications; intra-chromosomal 
rearrangements; translocations). 
 
A total of 19,482 sequences surrounding the breakpoint junctions at either side was 
examined (200 bp from each side of the breakpoints) and discovered 97 consensus motifs 
across the various event types: 15 motifs in deletions, 27 in inversions, 7 in duplications, 
31 in intra-chromosomal rearrangements and 17 in translocations (Figure 3-19). The 
manual curation of the top five most frequent motifs in each event type revealed that most 
of the discovered motifs were unique to the respective event types except ‘RAAATR’, 
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which were shared between deletion and inversion event types (Table 3-4). This motif 
‘RAAATR’ represents a consensus DNA pattern of ‘AAAATA’ with some nucleotide 
degeneracy at the 1st and 6th position.  
 
The signal of As enrichment has been seen across different event types of 
pancreatic tumours. In particular, the duplication event type revealed a DNA pattern of 
‘AAAAAAA’ with some nucleotides degeneracy at 5th and 6th position (derived from the 
motif ‘AAAAWWA’) as the top most frequent DNA pattern in the regions surrounding the 
breakpoints (Figure 3-20). The enrichment of As observed here is consistent with what 
have been previously reported whereby the transposon element insertion (TEI) resulted in 
duplication of target sites and were frequently found in As rich DNA regions (Lee et al., 
2012; Prak and Kazazian, 2000). Therefore, the signal of As in duplication event type 
highlights the possibility of retrotransposition activity presents in this cohort of pancreatic 
cancer genomes.  
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Figure 3-19 Consensus motifs at breakpoint junction in each event type. The 
frequency of the enriched motifs was plotted against the 92 discovered motifs. The graph 
is ordered by the frequency of matching motif patterns in each genome subtype. Bars are 
coloured according to the event type – deletion, blue; inversion, red; duplication, grey, 
intra-chromosomal, green; translocation, light blue. The abbreviation for the degenerate 
bases is found in Supplementary Table 3-2. 
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Table 3-4 Comparison of the discovered motifs across event types of PDAC 
Motifs Deletion Duplication Intra-chr Inversion Translocation 
ASAGA 49.0% - - - - 
RAAATR 47.1% - - 35.1% - 
GGCRTGR 6.2% - - - - 
ACGTR 6.0% - - - - 
CNGCCTCC 5.9% - - - - 
AAAAWWA - 27.6% - - - 
GCAGTGR - 8.6% - - - 
KATTACA - 7.6% - - - 
AGGCTGGW - 6.5% - - - 
CYGTCTC - 6.5% - - - 
RGARAA - - 37.9% - - 
AAATAH - - 37.4% - - 
CMCASC - - 16.4% - - 
AGGMAG - - 14.9% - - 
CACG - - 14.4% - - 
AGRAAR - - - 37.4% - 
AWATAY - - - 28.3% - 
CYGYCTC - - - 8.5% - 
AGSTGKG - - - 8.4% - 
RGAAA - - - - 59.5% 
ATWTWT - - - - 37.7% 
AAAATAHA - - - - 10.7% 
AGGCNGG - - - - 9.8% 
ACAYACA - - - - 6.4% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-20 Consensus motif in the surrounding sequence of duplications. The 
enriched motifs were generated from 166 sequences that surround the breakpoint junction 
at either side of duplication event type. The consensus pattern of duplication is ‘AAAAAAA’ 
with some nucleotides degeneracy at 5th and 6th position. 
Duplication 
166/602 
(27.6%) 
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3.4 Discussion 
In this chapter, I presented an analysis of somatic rearrangement breakpoints in 
pancreatic primary tumours. Mapping the breakpoints to base resolution allows precise 
annotation of the chromosomal rearrangements and the identification of characteristics of 
breakpoints could give us clues about the potential mechanisms involved in DNA repair 
and rearrangements formation.  
 
 The compendium of somatic rearrangements obtained from 120 pancreatic tumours 
showed that each pancreatic cancer genome displayed distinct patterns of somatic 
rearrangements and breakpoints characteristics. A total of 10,074 high confidence somatic 
rearrangements were identified across these tumours. Intra-chromosomal rearrangements 
were the most prevalent somatic event type and inversion formed the most common 
subcategory. Of 10,074 somatic rearrangements, 95% of the somatic rearrangements 
were identified with split contig alignment and could be used to characterise the 
breakpoints junctions. The majority of the breaks exhibit the microhomology characteristic 
(74.8%). Approximately 67% of these somatic rearrangements harboured 1 to 5 bp short 
overlapping bases suggesting that the NHEJ might be the predominant DNA repair 
mechanisms in this cohort of pancreatic cancer genomes (Chen, 2001; Yang et al., 2013). 
However, it should also be noted that the different length of homology are shared across 
multiple mechanisms according to these literatures (Conrad et al., 2010; Hastings et al., 
2009; Lam et al., 2010; Lee et al., 2007; Yang et al., 2013). For example, NHEJ is able to 
generate deletions with blunt end (0 bp), microhomology (length 1 to 5 bp), non-templated 
sequence insertion (length 1 to >20 bp) and genomics shards (length >20 bp).   
 
Recent work by the members of QCMG showed that the genomic distribution of 
somatic rearrangements in cancer genomes could stratify pancreatic cancer into 4 
genome subtypes – focal, scattered, stable and unstable (Waddell et al., 2015). The 
unstable subtype was frequently associated with BRCA mutation and a high BRCA 
mutational signature. Tumours with unstable genomes responded better to platinum-based 
therapy suggesting that unstable genome could be potential candidate biomarker for 
therapeutic responsiveness. However, in that study approximately 28% of tumours with 
unstable genome did not harbour BRCA mutation or had low BRCA mutational signature 
indicating that there are other mechanisms resulting in genome instability. Here, we looked 
into the characterization of breakpoints junctions and the sequence context surrounding 
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the breakpoints across a large cohort of primary pancreatic tumours to investigate what 
are the potential mechanisms driving the formation of somatic rearrangements.  
  
BRCA genes are known to be involved in DNA repair via the HR pathway 
(Gudmundsdottir and Ashworth, 2006; Zhang and Powell, 2005) while the characteristic of 
microhomology has been associated with NHEJ repair mechanism (Chen, 2001; Yang et 
al., 2013). The results presented here showed that BRCA deficient tumours (point 
mutation and high BRCA mutational signature) of both PDAC and AOCS often have higher 
frequency of somatic breakpoints with microhomology of 1 to 5 bp. This suggests that due 
to the deficiency of BRCA in the HR pathway, the DNA repair machinery of the cancer 
cells might switch to the ‘error-prone’ NHEJ, which uses microhomology as an alternative 
mechanism in order to repair the broken chromosomes (Patel et al., 2011). Otherwise, for 
cases where HR mechanism is still intact, the ‘accurate’ NHEJ could re-join the 
chromosomal breakage accurately and generate somatic rearrangements with blunt end 
characteristic (Pfeiffer et al., 2000). In agreement with the genome subtype analysis 
whereby the unstable subtype that was associated with HR defective pathway, has a lower 
frequency of breakpoints of blunt end characteristic when comparing to the other subtypes. 
In addition, there may be a difference in breakpoint characteristics pattern between 
BRCA1 and BRCA2 suggesting that they might have a distinct function in the HR pathway. 
 
BRCA1/2 genes play an important role in DNA repair mechanisms. It has been 
shown that tumours with defective BRCA pathway responded better to platinum-based 
therapy (D'Andrea, 2003). Cells with BRCA1 or BRCA2 mutation are highly sensitive to 
PARP1 inhibition. The loss of PARP1 activity seems to lead to an accumulation of multiple 
DNA lesions and result with an increase chromosome instability leading specifically tumour 
cell death (Farmer et al., 2005). As previous work from QCMG showed that a BRCA 
mutation does not always correlate with a BRCA-like mutational signature suggesting that 
some mutations are not significant, while a tumour can have a BRCA-like mutational 
signature but no BRCA1/2 mutation may suggest that other members of HR pathway are 
mutated or perturbed. Therefore, the different breakpoint characteristics between tumours 
with BRCA mutation and BRCA mutational signature reinforce previous evidence that a 
subtype of pancreatic tumour might have deficiency in the HR pathway and could 
response to PARP1 inhibitors.   
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One important weakness in these analyses is the inability of detecting extensive 
homology at the chromosomal breakage leading to a bias observation toward 
microhomology at breakpoints. However, this is a limitation of most structural variation 
detection tools using short sequencing reads (≤300 bp) (Onishi-Seebacher and Korbel, 
2011) but could possibly be resolved by using the alternative sequencing technologies that 
produces long reads of up to 15 kb.    
 
The analysis of DNA sequences surrounding the breakpoints has provided insight 
of biological activities or mechanisms driving the formation of somatic rearrangements. We 
learnt that these formations of somatic rearrangements in pancreatic tumours among 
events such as genome subtype and event type have a significant preference for DNA 
regions enriched for A+Ts. Possible mechanisms that could associate with these 
observations are:  
 
(1) Retrotransposition activity. Somatic transposon element (TE) insertions have 
been shown to be involved in tumorigenesis in other human cancers (Helman et al., 2014; 
Lee et al., 2012). Our results showed that majority of the somatic rearrangements 
displayed enrichment of A+Ts around the DNA sequence surrounding the breakpoints 
throughout the four genome subtypes and different event types. The motifs in genome 
subtypes are ‘RAAATA’, ‘ARAGAAA’, ‘RAAATR’, ‘AWATAY’, ‘AAATRY’, ‘AAANAAAA’, 
and ‘AAATAAW’. For the different event types, the motifs include ‘RAAATR’, ‘AAAAWWA’, 
‘AAATAH’, ‘AWATAY’, ‘ATWTWT’, and ‘AAAATAHA’. In particular, the most frequent DNA 
motif in duplication event was AAAAWWA represented by a consensus DNA pattern of 
‘AAAAAAA’. Previous studies have reported similar consensus motif patterns (e.g. 
‘TTAAAA’ and ‘TTTTAAAAA’) at the target site of somatic retrotransposons insertions 
associated with duplications of human cancer genomes (Helman et al., 2014; Lee et al., 
2012; Prak and Kazazian, 2000).  
 
(2) Association with chromosomal fragile sites. The fragile sites have been 
described to be associated with A+Ts rich regions and also known as one of the 
contributors to genomic instability in human disease especially cancers (Arlt et al., 2006; 
Barlow et al., 2013; Gandhi et al., 2010). Studies have shown that fragile sites could arise 
from chromatin modification (Jiang et al., 2009) and hypomethylation (Shann et al., 2008) 
which play a role in the formation of structural rearrangements in human cancers. 
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In summary, the different composition of event types and differences between the 
breakpoints characteristics across the pancreatic primary tumours suggest that the 
underlying mechanisms of somatic rearrangements formation in pancreatic carcinogenesis 
are complex with potentially multiple mechanisms acting within a single genome. Overall, 
the analyses highlight that NHEJ is an active DNA repair mechanism during the 
development of pancreatic cancer. The identification of breakpoints with microhomology 
may indicate that HR pathway is defective in a subgroup of pancreatic tumours. 
Furthermore, the analysis of the DNA sequences surrounding the breakpoints showed the 
enrichment of A+Ts that might indicate that retrotransposons and fragile sites could 
associate with the number and the distribution of somatic rearrangements in pancreatic 
cancer, however, this aspect of the analysis need to be further investigated.  
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3.5 Supplementary Material 
Supplementary Table 3-1 Summary of verified somatic rearrangements breakpoints 
Donor id Event type chr from 
chr from 
breakpoint 
chr from 
strand 
chr 
to 
chr to 
breakpoint 
chr to 
strand Verified Identified breakpoints 
Strand 
info 
APGI_1959                                Intra-chromosomal 10 127115886 + 10 115575262 + no -  
APGI_1959                                Intra-chromosomal 10 128138324 + 10 132334501 + no -  
APGI_1959                                Inversion 10 128143345 - 10 131927831 + no -  
APGI_1959                                Intra-chromosomal 10 131182809 + 10 124275387 + no -  
APGI_1959                                Intra-chromosomal 10 131357885 + 10 80347920 + no -  
APGI_1959                                Inversion 10 81884712 - 10 131680198 + yes -  
APGI_1959                                Intra-chromosomal 10 81934545 + 10 81937501 + yes -  
APGI_1959                                Deletion 10 112178601 + 10 112224869 + yes -  
APGI_1959                                Amplified Inversion 10 131220180 - 10 131223531 + yes - 
 
APGI_1959                                Intra-chromosomal 10 131679280 + 10 81934364 + yes -  
APGI_1959                                Deletion 10 132520931 + 10 132626399 + yes -  
APGI_1959                                                               Amplified Inversion 10 132691801 + 10 132692644 - yes - 
 
APGI_1959 Intra-chromosomal 10 127115886 + 10 115575262 + no -  
APGI_1959                                                               Deletion 10 90698204 + 10 118965300 + yes chr10: 118965300- 90698204  -/- 
APGI_1959                                                               Deletion 10 111236293 + 10 125812179 + yes chr10:111236293-125812179  +/+ 
APGI_1959                                                               Intra-chromosomal 10 125985379 + 10 111257993 + yes chr10:111236293-125812179  +/+ 
APGI_1959                                                               Foldback Inversion 10 111822448 + 10 116136459 - yes chr10:116136459-111822448  +/- 
APGI_1959                                                               Foldback Inversion 10 112783819 + 10 117872128 - yes chr10:117872128-112783819  +/- 
APGI_1959                                                               Foldback Inversion 10 117323037 - 10 118948105 + yes chr10:118948105-117323037  -/+ 
APGI_1959                                                               Intra-chromosomal 10 124171213 + 10 110529485 + yes chr10:124171213-110529485  +/+ 
APGI_1959                                                               Intra-chromosomal 10 126565271 + 10 126918647 + yes chr10:126565264-126918647  +/+ 
APGI_1959                                                               Intra-chromosomal 10 127060916 + 10 125985476 + yes chr10:127060916-125985476  +/+ 
APGI_1959                                                               Amplified Inversion 10 130765200 - 10 130765864 + yes 
chr10:130765200-
130765864 -/+ 
APGI_1959                                                               Tandem 10 131183502 + 10 127081152 + yes chr10:131183502- +/+ 
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Duplication 127081152  
APGI_1959                                                               Duplication 10 131553675 + 10 104959011 + yes chr10:131553675-104959011 +/+ 
APGI_2049                                Intra-chromosomal 7 145759290 + 7 109067344 + no -  
APGI_2049                                Foldback Inversion 7 146696184 - 7 147399313 + no -  
APGI_2049                                Intra-chromosomal 6 162287635 + 6 162295523 + no -  
APGI_2049                                Foldback Inversion 3 20319547 + 3 174852757 - yes -  
APGI_2049                                Translocation 7 109066841 + 3 191369830 + yes -  
APGI_2049                                Translocation 7 109613754 + 3 21654066 + yes -  
APGI_2049                                Translocation 7 114376753 + 3 175416919 + yes -  
APGI_2049                                Intra-chromosomal 9 9542252 + 9 9544210 + yes -  
APGI_2049                                Translocation 15 29104579 + 11 31548728 + no -  
APGI_2049                                Inversion 18 18530073 + 18 19381954 - no -  
APGI_2049 Intra-chromosomal 13 68878214 + 13 69058982 + yes -  
APGI_2049 Deletion 17 11097052 + 17 12862481 + yes chr17:12862481-11097058  -/- 
APGI_2049 Amplified Inversion 17 15210082 - 17 15211382 + yes 
chr17:15210082-
15211382  -/- 
APGI_2049 Inversion 17 15281828 + 17 50164473 - yes chr17:50164473-15281828  +/- 
APGI_2049 Inversion 18 18777462 - 18 19385721 + yes chr18:19385724- 18777462  -/+ 
APGI_2049 Deletion 20 61035468 + 20 61322801 + yes chr20:61035473-61322805  +/+ 
APGI_2049 Intra-chromosomal 23 7245498 + 23 7190442 + yes chr23:7190442-7245504  -/- 
APGI_2049 Translocation 3 191163264 + 7 146440446 + yes chr7:146440446-chr3:191163270  -/- 
APGI_2049 Translocation 3 174865868 + 7 146704618 - yes chr7:146704618-chr3:174865879  +/- 
APGI_2049 Foldback Inversion 7 89045573 + 7 107390164 - yes chr7:89045585-107390164   +/- 
APGI_2156 Intra-chromosomal 2 86639146 + 2 86640479 + no -  
APGI_2156 Deletion 16 78661636 + 16 78663235 + no -  
APGI_2156 Intra-chromosomal 22 36834501 + 22 36840002 + no -  
APGI_2156 Foldback Inversion 4 184211805 - 4 184545554 + yes -  
APGI_2156 Intra-chromosomal 6 44601759 + 6 44601823 + no -  
APGI_2156 Intra-chromosomal 7 48898896 + 7 48899988 + no -  
APGI_2156 Deletion 12 52330742 + 12 52426239 + no -  
APGI_2156 Foldback Inversion 1 228189395 + 1 228316922 - yes chr1:228189395-228316922  +/- 
APGI_2156 Foldback Inversion 1 228285225 - 1 228324721 + yes chr1:228325035-228285452  +/- 
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APGI_2156 Deletion 10 84254184 + 10 84287402 + yes chr10:84254182-84287402  +/+ 
APGI_2156 Deletion 16 78617053 + 16 78644950 + yes chr16:78617053-78644951  +/+ 
APGI_2156 Deletion 16 78715249 + 16 78782389 + yes chr16:78715249-78782389   +/+ 
APGI_2156 Tandem Duplication 20 14625647 + 20 14574229 + yes 
chr20:14625651-
14574229  +/+ 
APGI_2156 Deletion 3 60499811 + 3 60615358 + yes chr3: 60499811-60615358  +/+ 
APGI_2156 Deletion 3 116111888 + 3 116755875 + yes chr3:116755875-116111887  -/- 
APGI_2156 Intra-chromosomal 3 60345191 + 3 60339070 + yes chr3:60345191-60339072   +/+ 
APGI_2156 Foldback Inversion 4 184211274 + 4 184567325 - yes chr4:184567323-184211274  +/- 
APGI_2156 Deletion 4 184271711 + 4 184571354 + yes chr4:1845713454-184271711   -/- 
APGI_2156 Intra-chromosomal 9 21985014 + 9 22621446 + yes chr9: 21985014-22621446  +/- 
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Supplementary Table 3-2 Abbreviations for degenerate bases used in this chapter 
Degenerate base Actual bases 
N A or C or G or T 
B C or G or T 
D A or G or T 
H A or C or T 
V A or C or G 
K G or T 
M A or C 
R A or G 
S C or G 
W A or T 
Y C or T 
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4 Chapter 4  
 
Identification of personalized DNA-based biomarkers for 
pancreatic cancer and the assessment of whether they can be 
used to monitor tumour burden and response to chemotherapy 
 
4.1 Introduction – Somatic mutations as biomarkers in circulating cell free DNA 
The definition of a cancer biomarker by National Cancer Institute is “a biological molecule 
found in blood, other body fluids or tissues that is a sign of normal or abnormal process, or 
of a condition or disease”. Somatic mutations such as structural rearrangements or point 
mutations are features of cancer genomes. Thus, they hold great promise for patient 
specific biomarkers which can be used to either predict response to treatment or monitor 
relapse. Previous studies have shown that the primary tumour releases DNA fragments 
into the circulation carrying characteristics of the tumour, which could reflect diverse 
pathological states (Leary et al., 2010; McBride et al., 2010). 
 
4.1.1 Approaches for monitoring circulating tumour DNA 
Over the years, studies have demonstrated the quantification of tumour specific mutations 
in circulating cell free DNA (cfDNA) using digital PCR (Sykes et al., 1992; Vogelstein and 
Kinzler, 1999) or next generation sequencing (Rusk and Kiermer, 2008). 
 
 Studies have shown that tumour specific chromosomal rearrangements are 
detectable in circulating cfDNA obtained from serum or plasma of cancer patients. Leary et 
al. (Leary et al., 2010) developed an approach called “Personalised Analysis of 
Rearrangement Ends” (PARE) to identify somatic rearrangements that are unique to each 
patient. This approach uses next generation sequencing of the primary tumour to detect 
tumour specific somatic rearrangements; a quantitative PCR assay is then used to detect 
and quantify the rearrangements in the cfDNA. McBride et al. presented a similar assay to 
detect and quantify tumour specific rearrangements in plasma or serum of patients with 
metastatic breast and bone cancers (McBride et al., 2010).  
 
 Another approach is to detect specific somatic mutations in cfDNA, which are at 
higher frequency in a particular cancer. These mutations could be “hotspot” mutations, 
which occur at the same position within a gene. For example, PIK3CA in breast cancer 
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(Beaver et al., 2014), KRAS and BRAF in colorectal cancer and EGFR in non-small cell 
lung cancers (Yung et al., 2009). The digital PCR (dPCR) technology is used and directly 
counts the number of target molecules to give an absolute quantification of any rare allele 
without relying on reference standards or endogenous controls. PCR reaction is 
partitioned into hundreds or thousands individual PCR reactions for amplification 
depending on the platform. The number of amplified molecules will be estimated by 
Poisson algorithm. A number of vendors have launched commercial instruments that allow 
this technology to be used for quantification of ctDNA (Table 4-1). Of these, two dPCR 
instruments were evaluated in this chapter to quantify circulating cfDNA. A detailed review 
of dPCR instruments has been reported by Monya Baker (Baker, 2012).  
 
Table 4-1 Comparison of potential dPCR instruments for circulating DNA project 
Name of the instruments 
(Vendor) Chemistry 
Sample per 
plate/chip/strip 
Number of 
reactions per 
sample 
Reaction 
volume 
Quantstudio® 3D digital PCR 
System (Life Technologies) 
 
chip-based 48 samples/plate 64 reactions 100 µL 
BioMark™ HD System 
(Fluidigm Corporation) 
 
chip-based 12 samples/chip 765 reactions 8 µL 
QX200 Droplet Digital PCR 
(Bio-Rad) 
 
droplet-
based 8 samples/strip 20,000 droplets* 20 µL 
RainDrop™ Digital PCR 
System (RainDance 
Technologies) 
 
droplet-
based 8 samples/strip 
10,000,000 
droplets* up 50 µL 
     
*A droplet is equivalent to one reaction 
 
With the advent of genomic technologies, next generation sequencing technology is 
an alternative approach for mutation detection in cfDNA. Different sequencing methods 
have been used to detect tumour specific mutations in plasma or serum of cancer patients 
(Leary et al., 2012; Murtaza et al., 2013; Narayan et al., 2012). This includes whole 
genome sequencing, exome sequencing, and target amplicon sequencing. Whole genome 
sequencing and exome sequencing can identified novel mutations without the needs to 
focus on reported mutations. In contrast, targeted amplicon sequencing focuses on a 
single or panel of predefined or hotspot mutations. In principle, the quantification using 
sequencing technologies make use of the knowledge of genomic position of known 
mutations which the frequency can be read out directly from the sequencing data. 
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However, the minimum mutant allele frequency that can be detected, will depend on the 
read depth background rates of non-reference reads (error rate).  
 
4.1.2 Current biomarker for pancreatic cancer 
The most widely used and investigated biomarker for pancreatic cancer is cancer antigen 
19.9 (CA 19.9). It was first discovered through monoclonal antibody studies of colorectal 
cancer cell lines (Koprowski et al., 1979), and was later showed that pancreatic cancer 
patients have increased levels of CA 19.9 (Steinberg, 1990). However, CA 19.9 marker 
has limitations such as inadequate sensitivity and specificity. Elevated levels of CA 19.9 
are observed in other gastrointestinal cancers including gastric and colorectal cancers 
(Duffy, 1998). CA 19.9 lacks sensitivity in detecting small pancreatic tumours (Steinberg, 
1990). Assays for CA 19.9 have been inconsistent producing different results in different 
laboratories (Duffy et al., 2010) and the expression of CA 19.9 is only subjected to 
population who carries Lewis A blood group antigen (Takasaki et al., 1988). Together, 
these limitations reinforce the need for a more accurate biomarker in clinical management 
for pancreatic cancer patients.  
 
4.1.3 Alternative biomarkers in pancreatic cancer 
Cancer genomes harbour tens to thousands of somatic mutations in its pathogenesis and 
could be used as potential biomarkers (Birnbaum et al., 2011; Campbell et al., 2010). The 
PARE assay requires sequencing of a primary tumour (Leary et al., 2010), however, in the 
case of pancreatic cancer, tumour material is not available for 80% of patients whom have 
non-resectable disease. However, it is known that the mutation of KRAS gene is found in 
over 90% of pancreatic cancer (Thomas et al., 2007) and most of these mutations occur at 
G12 amino acid.  
 
 Therefore, in this chapter I explore both PARE assay (personalized approach) and 
the quantification of KRAS mutation (generic approach) in circulating cfDNA with the aim 
to investigate whether such mutations could be used as biomarkers in pancreatic cancer.   
 105 | P a g e 
4.2 Material and methods 
Different approaches were used to test the use of tumour specific somatic mutations as 
ctDNA biomarkers to monitor tumour burden and response to chemotherapy in patients 
with pancreatic cancer. A schematic of the work is illustrated in Figure 4-1. Essentially, two 
approaches were used: personalized tumour specific rearrangements and generic 
recurrent KRAS mutation as biomarkers. I first designed primers and probes targeting 
small amplicons (<200 bp) which spanned the rearrangement breakpoints or KRAS 
mutation. I then attempted to quantify the mutations in serum or plasma obtained from 
patients with pancreatic cancer during the disease course to evaluate the association of 
mutation load in circulation with tumour burden of individuals.  
Determine the sensitivity of sequencing and PCR based methods in 
detecting mutation in serum/plasma   
Design primers and 
probes for smaller 
amplicon  
(< 200 bp) spanning 
breakpoint 
Verified somatic 
rearrangements Confirm KRAS in tumours 
PCR detection of KRAS 
mutation 
Somatic  
Rearrangements KRAS mutation 
Quantify the mutations in the serum/plasma with appropriate 
instrument 
Associate the quantification of mutant circulating DNA with tumour 
burden  
Design primers with 
barcode 
PCR detection of somatic 
rearrangements 
 
Figure 4-1. Schematic analysis for detecting tumour specific mutations in serum or 
plasma.  
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4.2.1 Patient serum or plasma samples 
Patients were recruited to the Australian Pancreatic Cancer Genome Initiative (APGI) and 
have given informed written consent for the participation. A total of 28 serum or plasma 
samples were collected from five patients (APGI 1830, 1953, 1959, 2302, 2353) during 
their course of therapy. Circulating DNA was isolated from 0.8 mL to 1.7 mL serum or 
plasma using QIAamp Circulating Nucleic Acid kit (Qiagen) following the manufacturer’s 
instruction. Note: Patients were recruited by the APGI Team coordinated by Amber 
Johns, and the extraction of DNA from the serum was performed by Dr. Venessa 
Chin, Garvan Institute of Medical Research.  
 
4.2.2 Quality control and quantification of serum or plasma DNA 
Upon receiving the serum or plasma DNA samples, the size, quality and quantity of the 
serum or plasma DNA were assessed on Agilent 2100 BioAnalyzer using the High 
Sensitivity DNA Kit. An example of Bioanalyzer profile of sample that passed and failed 
the quality check is shown in Figure 4-2. 
 
Fail%Pass%
Lower marker Upper marker Lower marker Upper marker 
cfDNA cfDNA 
cellular gDNA 
 
Figure 4-2 Agilent profile showing pass and fail of the QC check for cfDNA. The size 
of the nucleic acid is on the x-axis and the fluorescent intensity is on y-axis. The vertical 
blue indicate the expected size of cfDNA (approximately 130 to 200 bp). Sample that 
passes QC indicates that the size of the serum or plasma DNA lies within expected range. 
For a sample that fails QC, the DNA profile indicates that cfDNA is contaminated with 
genomic DNA. 
 
Of the 28 samples received, 15 serum or plasma DNA were detected within the 
expected size between 130 and 200 bp, however, many were in small quantity and volume 
(0.14 ng/uL to 5.3 ng/uL; >10 uL to 20 uL) (Supplementary Table 4-1). The remaining 13 
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did not pass the quality check as they were either contaminated with genomic DNA or 
DNA was below the detection limits.  
 
4.2.3 Whole genome amplification of serum or plasma DNA 
Illumina Genomic DNA Sample Prep Kit was used for whole genome amplification (WGA) 
of the circulating cfDNA. The amplification was carried out by the ligation of adaptors to 
cfDNA (fragments 130 to 200 bp) and PCR amplification (i.e. 18 cycles), following the 
manufacturer’s instruction. The amount of serum or plasma used for amplification and 
quantification is listed in Supplementary Table 4-2.   
 
4.2.4 Personalised analysis – Somatic rearrangement 
Identification of somatic rearrangements 
Whole genome sequencing of primary tumour and matched normal from patient APGI 
1959 was performed and 27 somatic rearrangements were identified using qSV which was 
previously described in Chapter 3. A somatic deletion of 50 kb spanning across 
chr10:81,937,567-131,680,490 was selected as a potential personalised biomarker. This 
event resulted a deletion of the PTEN gene and so was a suitable event for testing, as it is 
likely to be important to the tumour, therefore will not get lost during tumour progression. 
 
Primers and probes for somatic rearrangement 
Primers and probes were designed to detect tumour specific rearrangement (deletion) in 
the serum using custom TaqMan® assay design tool (Invitrogen) and generated a PCR 
product of 180 bp. The TaqMan® assay includes DNA template, a pair of PCR primers 
and a sequence-specific TaqMan® probes (Supplementary Table 4-3).  
 
4.2.4.1 Digital PCR of somatic rearrangement 
BioMark system (Fluidigm) 
Digital PCR (dPCR) was carried out in 12.765 digital array chip which consists of 12 
panels (sample wells) and each panel partitions the sample premixed with PCR reagents 
into 765 individual PCR reaction, allowing quantification of target sequences. Each panel 
was set up with DNA sample, 5 µL TaqMan Gene Expression Master Mix (Applied 
Biosystems), 0.5 µL of 20X GE sample loading reagent (Fluidigm) and 0.5 µL of 20X 
TaqMan® gene expression assay in a final volume of 10 µL. Then, the digital array chip 
was primed and the samples were loaded by NanoFlex 4IFC Controller (Fluidigm). The 
PCR amplification was carried in the BioMark Real-time PCR system using a cycle profile 
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of initial at 50°C for 2 min and incubation at 95°C for 10 min followed by 40 cycles of 95°C 
for 15 sec and 58°C for 1 min. Digital PCR analysis was done using BioMark dPCR 
analysis software version 3 (Fluidigm). 
 
QX100™ Droplet Digital™ PCR System (Bio-Rad) 
The emulsion PCR approach used by the droplet dPCR allows partition of the PCR 
reaction in a higher number of partitions than chip-based increasing the dynamic range of 
the quantification. Each reaction mixture contains 12.5 µL of 2X ddPCR master mix (Bio-
Rad), 1.25 µL of 40X TaqMan® gene expression assay, and DNA sample in a final volume 
of 25 µL. The prepared reactions were loaded into individual wells of the disposable 
droplet generator cartridge with 70 µL droplet generation oil (Bio-Rad), and then into the 
QX100 droplet generator (Bio-Rad) to generate ~20,000 emulsion droplets. The emulsified 
droplets were amplified using a cycling profile of 50°C for 2 min and incubation at 95°C for 
10 min followed by 40 cycles of 95°C for 15 sec and 58°C for 1 min. The output was 
analysed with QuantaSoft analysis software 1.3.2.0 (Bio-Rad).  
 
4.2.4.2 Quantification of ctDNA using somatic rearrangement 
Patient APGI 1959: A serum sample was collected during chemotherapy and passed QC. 
The dPCR technologies (Fluidigm and Bio-Rad) were used to quantify tumour specific 
rearrangement (deletion) in the circulation of this patient. Taking an assumption that whole 
genome amplified (WGA) serum has sufficient amount of tumour DNA molecules, 1 in 5 
serial dilutions were carried in WGA serum DNA ranging from 1:125 to 1:78,125 to 
estimate the number of copies of tumour DNA.  
 
4.2.5 Generic analysis – recurrent KRAS mutation 
Preparation of serial dilution of tumour DNA and germline DNA samples 
Primary tumour DNA was mixed at known concentration with matched normal DNA to 
determine the sensitivity of the quantification of sequencing and dPCR instruments as well 
as acting as controls when quantifying mutation in cfDNA of cancer patients. Primary 
tumour DNA was diluted in normal DNA as a 1 in 5 dilution until reaching 1:78,125. The 
input amount of DNA varied between 5 to 50 ng depending on the methods and/or 
instruments used. The actual amount of tumour DNA in each serial dilution depends on 
the cellularity of the primary tumour analysed.  
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4.2.5.1 Next generation sequencing 
Primers for KRAS mutation 
Primers were designed to detect KRAS mutations at KRAS exon 2, chr12: 25398284 (C>T 
– patient APGI 1953) and exon 3, chr12: 25380277-25380278 (GA>TT – patient APGI 
2353). Primers sequences are listed in the Supplementary Table 4-3. For nested PCR, the 
first pair of primers were designed further away from the target region and generated PCR 
products of size <200 bp. The second pair of primers was designed nearer to the target 
region to generate PCR products (Supplementary Table 4-3).  
 
Preparation of sequencing libraries and sequencing 
Serial dilutions of primary tumour DNA and plasma DNA samples were subjected to an 
initial round of 18 PCR cycles, followed by a second round of 35 PCR cycles to incorporate 
sequencing adaptors and barcodes. The barcoded amplicons (DNA libraries) were 
analysed using Agilent 2100 BioAnalyzer to ensure expected insert size of <200 bp. The 
PCR products were pooled and purified using AMPure XP beads using a bead:DNA 
volume ratio of 1.8:1. The library was then quantified using Qubit Flurometer (Invitrogen) 
and subjected to Ion Torrent PGM (1 x 200 bp run) and Illumina MiSeq (2 x 150 bp run) 
amplicon sequencing according to manufacturers’ instruction. Note: Sequencing was 
performed by QCMG sequencing team. 
 
Analysis of sequencing data 
Sequencing reads were aligned to the reference genome (hg19) using TMAP (Ion Torrent) 
or BWA (MiSeq). The frequency of the mutated allele (KRAS) was measured by the ratio 
of the number of reads with the mutant allele and the total read counts at the target 
position. Note: Pre-processing of the data was performed by QCMG informatics team. 
 
4.2.5.2 Digital PCR of KRAS mutation 
Primers and probes 
Primers and probes were designed to detect KRAS reference base (VIC) and mutated 
base (FAM) at KRAS exon 2, chr12: 25398284 (C>T, patient APGI 1959) and exon 3, 
chr12: 25380277- 25380278 (GA>TT, patient APGI 2353). The TaqMan® assay includes 
DNA template, a pair of PCR primers and two sequence-specific TaqMan® probes 
(Supplementary Table 4-4).  
 
BioMark system (Fluidigm) 
Refer to previous section.  
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QX100™ Droplet Digital™ PCR System (Bio-Rad) 
Refer to previous section.  
 
4.2.5.3 Quantification of ctDNA using KRAS mutation 
Patient APGI 1953: The quantification of KRAS mutation (chr12: 25398284, C>T) in the 
plasma of this patient was performed using PGM sequencing method. The serial dilutions 
of tumour DNA were used as standard controls. The range of tumour DNA per reaction 
varies from 6.9 ng to 0.0004 ng. Nested PCR was performed to amplify KRAS mutation in 
both WGA cfDNA and standard controls. Serial dilutions of the primary tumour and 
matched normal DNA, and WGA cfDNA from two different time points of the patient 
disease course (post-operation and during chemotherapy) were included in the 
sequencing assay.  
 
Patient APGI 2353: The quantification of plasma was carried out using dPCR method. The 
quantification of KRAS mutation was performed on WGA cfDNA collected during pre-
operation and post-operation (after 2nd and 7th day). Serial dilutions of tumour and 
matched normal DNA (total input of 72 ng (Bio-Rad) and 36 ng (Fluidigm) were prepared 
as standard controls. Mixtures were diluted 5 times until reaching 1:3,125. Each dPCR 
assay includes serial dilutions of the primary tumour and matched normal DNA, DNA 
template, PCR primers pair and sequence-specific TaqMan probe to capture GA>TT in 
KRAS mutation.  
 
 To increase the sensitivity, WGA cfDNA were then subjected to an extra round of 
18 PCR cycles using primers targeting KRAS regions prior to the quantification on dPCR. 
PCR amplified WGA plasmas were quantified in five replicates on two separate dPCR 
assays using both Fluidigm and Bio-Rad instruments.  
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4.3 Results 
4.3.1 Personalised analysis – somatic rearrangement 
Validation and detection of the tumour specific rearrangement biomarker 
Whole genome sequencing identified 27 somatic rearrangements in patient APGI 1959. A 
somatic deletion of 50 Mb which contains PTEN and is located at chr10:81,937,567-
131,680,490 was selected as tumour specific rearrangement biomarker. Primers were 
designed to amplify a 180 bp PCR product. Figure 4-3 shows that tumour specific 
rearrangement was verified as somatic in the primary tumour and can be detected in 
whole genome amplified cfDNA. The next step is to quantify the amount of tumour 
mutation in this sample as a proof of principal that this approach could be used as a 
biomarker to monitor tumour burden in pancreatic cancer.  
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Figure 4-3 Gel photo of PCR validation of a deletion event in patient APGI 1959. Lane 
1: Marker; Lane 2: Primary tumour DNA of patient APGI 1959 (positive control); Lane 3: 
Matched normal DNA (negative control); Lane 4: Whole genome amplified serum DNA; 
Lane 4: No template (negative control). (Data obtained from Nones et al., 2011) 
 
Quantification of ctDNA using the tumour specific rearrangement 
The Fluidigm BioMark quantification of the rearrangement (deletion) in the serum from 
patient APGI 1959 revealed that there were only 6 copies in the undiluted WGA cfDNA (24 
ng/reaction) (Figure 4-4). No positive reaction was detected in the samples with further 
dilutions of the WGA cfDNA. The analysis of the undiluted WGA cfDNA was also tested on 
QX100™ Droplet Digital PCR System generating same results with 6 positive copies of 
tumour specific mutant detected (Supplementary Table 4-5).   
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Figure 4-4 Analysis of ctDNA using Fluidigm BioMark System. (a) An illustration of 
TaqMan assay designed for dPCR. This is deletion event identified through whole genome 
sequencing of primary tumour from patient APGI 1959. With the knowledge of exact 
breakpoint, primers (black arrows) and fluorescent probes (red block) were designed to 
target the region spanning across the breakpoint position at chr10:81,937,866-
131,680,191. (b) Representative heat map of digital array panel - each square represents 
a PCR reaction. When a tumour specific rearrangement is amplified, signals from the 
probe can be detected indicates in red.  
 
4.3.2 Generic analysis – recurrent KRAS mutation 
Detection limit of sequencing based approach to detect KRAS mutation 
To determine the limit of detection of KRAS mutation, I compared sequencing results 
obtained from Ion Torrent PGM and Illumina MiSeq sequencers. The patient used for this 
experiment was APGI 1953 which contained a KRAS mutation (C>T) at position 
chr12:2539828. Serial dilution of tumour and matched normal DNA (20%, 4%, 0.8%. 
0.16%, 0.032%, 0.0064%, 0.000128% of tumour DNA) was prepared in a total of 50 ng. A 
round of pre-amplification was performed (nested PCR) on each dilution. Sequencing was 
performed on each serial dilution of the PCR products to an average fold coverage of 
350,000x (Ion Torrent) and 600,000x (MiSeq).  
 
Tumour-specific fluorescent probe 
81937866 
131680191 chr 10 
Patient 
APGI 1959 
a 
b Duplicate 1 Duplicate 2 
Undiluted whole genome 
amplified serum 
Primer pair 
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Ion Torrent PGM: To estimate the sequence error rate at this position, deep KRAS 
sequencing of germline DNA was performed. The estimated error rate is dependent on 
individual experiment and may vary between sequencing experiments and also at different 
positions in the genome. Here, the error rate was estimated to be 0.7% as the base 
change (C>T) was detected in 0.7% of the sequence reads in the germline DNA (Table 4-
2). Using the error rate as a benchmark, I identified that sample containing 0.8% tumour 
DNA (expected allele frequency of 0.3%) is the limit of detection for this patient at read 
depth of 350,000x.  
 
Illumina MiSeq: The detection limit of KRAS mutation was assessed in a similar 
manner that was described in PGM sequencing. Sequencing was performed on the MiSeq 
to a higher average read depth of 600,000x. The sequence error rate estimated by the 
KRAS mutation frequency in germline DNA was 0.3% (Table 4-2). These results suggest 
that MiSeq has a lower error rate and might be more applicable to cfDNA studies than Ion 
Torrent. However, in serial dilutions, the frequency of detected KRAS mutation had 
reached the error rate limit at sample containing 0.8% of tumour DNA (with expected allele 
frequency of 0.3%).   
 
Table 4-2 Detection limit of KRAS detection using PGM and MiSeq sequencing 
  Reads  count for each base    
% of tumour 
DNA 
Amount of 
tumour DNA 
(corrected 
based on 
cellularity) A C G T # count 
Frequency 
mutation 
detection (%)* 
Expected % of 
mutation 
detection^ 
PGM         
Germline DNA 
(0%) 0 ng 1337 342736 1544 2411 348028 0.7% 0.0% 
Tumour DNA 
(100%) 6.9 ng 1225 184717 1678 158976 346596 46.3% 34.5% 
1:5  
(20%) 6.9 ng 1013 329113 602 24009 354737 6.8% 6.9% 
1:25  
(4%) 1.4 ng 1766 400134 2352 11627 415879 2.8% 1.4% 
1:125 
(0.8%) 0.276 ng 1226 325423 1672 3518 331839 1.1% 0.3% 
1:625 
(0.16%) 0.0552 ng 1060 361852 651 526 364089 0.1% 0.0552% 
1:3,125 
(0.032%) 0.011 ng 742 273383 521 813 275459 0.3% 0.0110% 
1:15,625 
(0.0064%) 0.0022 ng 1226 348138 1561 2070 352995 0.6% 0.0022% 
1:78,125 
(0.000128%) 0.0004 ng 1020 357058 638 644 359360 0.2% 0.0004% 
MiSeq         
Germline DNA 
(0%) 0 ng 37 499679 50 1323 501089 0.3% 0.0% 
Tumour DNA 
(100%) 6.9 ng 110 245629 180 194257 440176 44.2% 34.5% 
1:5  
(20%) 6.9 ng 63 544385 118 41362 585928 7.1% 6.9% 
1:25  
(4%) 1.4 ng 68 626132 70 9387 635657 1.5% 1.4% 
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1:125 
(0.8%) 0.276 ng 44 515776 48 2436 518304 0.5% 0.3% 
1:625 
(0.16%) 0.0552 ng 74 645374 66 1874 647388 0.3% 0.0552% 
1:3,125 
(0.032%) 0.011 ng 85 721035 80 2263 723463 0.3% 0.0110% 
1:15,625 
(0.0064%) 0.0022 ng 75 695589 76 1831 697571 0.3% 0.0022% 
1:78,125 
(0.000128%) 0.0004 ng 73 708434 56 1609 710172 0.2% 0.0004% 
         
 
Summary table is based on serial dilution of tumour DNA in germline DNA from patient APGI 1953 with 
cellularity of 69%. Mutation was detected on KRAS exon 2, chr12 position 25398284, C>T, aa: G12D  
 
*Frequency mutation detection is the percentage of detected mutant molecules in a background of wild-
type DNA (sum of reads counts of the base change (T) divided by the sum of total reads counts at the 
target position (C+T) x 100%) 
 
^Expected percentage of mutation detection is calculated by taking into account of the cellularity and 
dilution of the analysed samples (cellularity of the analysed sample x tumour variant allele frequency 
50% x dilution factor) 
 
 
 Previously, it has been shown that sequencing to detect tumour specific mutations 
in cfDNA is limited by tumour content in the sample, sequencing error, the coverage and 
the type of base substitution (Forshew et al., 2012). In an attempt to increase performance 
of KRAS by MiSeq sequencing, an additional patient (APGI 2353) which contained a 
dinucleotide base mutation of KRAS on exon 3 at codon 60 and 61 (GA>TT) was tested. 
Sequencing was performed to a higher average read depth of 1,000,000x. The sequence 
error rate was estimated at 0.066% using the KRAS mutation frequency in germline DNA 
(Table 4-3). As expected, it reduced the error rate and resulted in an improvement in our 
limit of detection. The frequency of detecting KRAS mutation reaches the error rate limit at 
sample containing 0.16% of tumour DNA (with expected allele frequency of 0.12%). Note 
that the primary tumour sample of this patient had much lower tumour content (cellularity 
of 30%). This is another factor that influences the detection of the analysis and needs to 
be considered with caution. The results cannot be directly compared to other runs as 
conditions of the runs were varied (for example, coverage, tumour content and the type of 
base interrogated). Unfortunately, the assay cannot be repeated due to the limitations in 
the amount of DNA available. 
 
Based on the sequencing results, the error rates observed for benchtop sequencers 
at the KRAS position were 0.7% for PGM with an average read depth of 350,000x and 
0.3% for MiSeq with read depth of 600,000x. These results suggest that the MiSeq 
sequencer would be a more suitable instrument for quantifying mutation load in circulating 
cfDNA as the amount of tumour DNA in total population of cfDNA is usually extremely low 
in the blood (Diehl et al., 2005).  
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Table 4-3 Detection limit for KRAS mutation using MiSeq sequencing on a patient with a dinucleotide mutation 
 
 
Summary table is based on serial dilution of tumour DNA in germline DNA from patient APGI 2353 with cellularity of 30%. Mutation was detected on KRAS exon 
3, chr12 position 25380277- 25380278, GA>TT, aa: Q61K 
 
*Frequency mutation detection is the percentage of detected mutant molecules in a background of wild-type DNA (sum of reads counts of the base change (T) 
divided by the sum of total reads counts at the target position (C+T) x 100%) 
 
^Expected percentage of mutation detection is calculated by taking into account of the cellularity and dilution of the analysed samples (cellularity of the analysed 
sample x tumour variant allele frequency 50% x dilution factor) 
 
 
  Reads  count for double base change    
DNA mixture 
(% of tumour 
DNA) 
Amount of tumour 
DNA (corrected 
based on cellularity) AA AC AG AT CA CC CT GA GC GG GT TA TC TG TT # count 
Frequency 
mutation 
detection (%)* 
Expected % 
mutation 
detection^ 
Germline DNA 
(0%) 0 ng 592 1 1 0 13 0 0 940229 193 1770 413 621 5 4 617 944474 0.066% 0% 
Tumour DNA 
(100%) 3.0 ng 731 0 0 17 38 4 436 993971 245 1833 1154 1386 385 64 199360 1199643 16.706% 15.0% 
1:5  
(20%) 3.0 ng 708 1 0 2 44 3 102 1112327 241 2118 685 1055 76 17 48888 1166289 4.210% 3.0% 
1:25  
(4%) 0.6 ng 712 0 4 1 38 1 28 1133148 243 2272 557 807 17 5 9650 1147513 0.844% 0.6% 
1:125 
(0.8%) 0.12 ng 754 0 2 0 27 1 5 1291313 332 2476 614 799 10 4 3405 1299768 0.263% 0.12% 
1:625 
(0.16%) 0.024 ng 810 0 0 0 34 0 2 1210701 307 2454 571 798 5 4 1384 1217094 0.114% 0.024% 
1:3,125 
(0.032%) 0.0048 ng 776 0 0 1 48 1 3 1333446 305 2447 645 847 4 5 1051 1339614 0.079% 0.0048% 
1:15,625 
(0.0064%) 0.00096 ng 768 1 0 0 39 1 0 1172107 304 2239 630 780 5 7 947 1177846 0.081% 0.0010% 
1:78,125 
(0.000128%) 0.000192 ng 580 0 0 0 30 1 2 897109 180 1739 376 590 2 4 601 901237 0.067% 0.00019% 
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Performance of PCR based approach to detect KRAS mutation 
Digital PCR (dPCR) has been suggested to have higher sensitivity and precision than real-
time quantitative PCR (Baker, 2012). Therefore, in an attempt to improve sensitivity of 
KRAS detection, two different dPCR instruments were evaluated - the Fluidigm BioMark 
system (chip-based) and Bio-Rad QX100 droplet digital PCR system (droplet-based). 
 
Fluidigm BioMark System 
Tumour and matched normal DNA from patient APGI 2106 was used to prepare the serial 
dilutions. Patient APGI 2106 contained a KRAS mutation (C>G) at position chr12: 
25398285. In order to determine the optimal input amount of DNA for dPCR analysis in 
Fluidigm BioMark System, I used various amount of input DNA ranging from 5 ng to 50 ng. 
Duplicates were performed for 10 ng and 15 ng and showed a relatively consistency of 
detecting mutant DNA molecules between 0.8% and 20% of tumour DNA (10 ng: Pearson 
correlation coefficient = 0.99, p<0.0001; 15 ng: Pearson correlation coefficient = 0.98, 
p=0.0002). It was also found that the total amount of input DNA of 50 ng overloaded the 
system for Fluidigm dPCR analysis (data not shown), this is due to the number of 
partitions in a chip and thus, limits the volume of analysed sample. 
 
 In this case, the detection limit could not be determined as we do not have enough 
normal DNA to include as control. However, a positive relationship can be observed 
between the quantity of positive mutant molecules determined using Fluidigm BioMark 
system and the expected frequency of mutant molecules in each serial dilution across the 
different total amount of input DNA (5 ng: R2 = 0.99762, 10 ng: R2 = 0.99811 (avg.), 15 ng: 
R2 = 0.99181 (avg.), 30 ng: R2 = 0.99333) (Figure 4-5).  
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Figure 4-5 Performance of Fluidigm dPCR for the detection of KRAS mutation. 
Different total amount of input DNA mixture were analysed with dPCR – (a) 5ng total DNA, 
(b) 10 ng total DNA, (c) 15 ng total DNA, (d) 30 ng total DNA. The number of positive 
mutant molecules measured by dPCR assay is on the y-axis and the percentage of 
expected mutant molecules is on the x-axis. The number stated at the right corner of the 
plot is the maximum number of detected mutant molecules. The assay was designed to 
detect C>G base change at chr12: 25398285 (aa: G12R) in patient APGI 2106, which 
tumour DNA has 72.5% cellularity. The expected percentage of mutation detection is 
calculated by taking account of the cellularity and heterogeneity of the analysed sample 
(cellularity of the analysed sample x tumour variant allele frequency 50%). 10 ng and 15 
ng input DNA were performed in duplicates.  
 
QX100 droplet digital PCR system 
An experiment was also performed using emulsion-based instrument known as droplet 
digital PCR (ddPCR) which allows partition of reactions as droplets. The instrument 
provides a higher number of reactions (~20,000) than a chip-based instrument (765 
reactions). This higher number of reactions increases the dynamic range of emulsion PCR 
and allows accurate measurement of greater range of copies of alleles (Heyries et al., 
2011; Pinheiro et al., 2012). Thus, this instrument also allows a higher input of DNA that 
might be beneficial to cfDNA studies.  
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 A serial dilution experiment was performed in replicates of 30 ng and 60 ng total 
input DNA from patient APGI 1953. The number of mutant DNA molecules in both 30 ng 
and 60 ng input DNA was positively related to the estimated frequency of mutated allele in 
the serially diluted DNA mixture (Figure 4-6). The number of positive counts at 4% tumour 
DNA is 69 (Column – Run 1) when using total amount of 30 ng input DNA. By increasing 
the total amount of input DNA to 60 ng, the positive counts at 4% tumour DNA has 
achieved 136 (Column – Run 1). This may suggest that the rate of mutation detection 
increased when the amount of input DNA is higher (Figure 4-6, Supplementary Table 4-6) 
 
a b 
y"="16.034x"
R²"="0.99849"
0"
50"
100"
150"
200"
250"
300"
350"
0" 5" 10" 15" 20" 25"
#"
of
"p
os
i(
ve
"m
ut
an
t"m
ol
ec
ul
es
"
%"of"es(mated"mutated"molecules"
319 y"="28.43x"
R²"="0.99969"
0"
100"
200"
300"
400"
500"
600"
0" 5" 10" 15" 20" 25"
#"
of
"p
os
i(
ve
"m
ut
an
t"m
ol
ec
ul
es
"
%"of"es(mated"mutated"molecules"
570 
30 ng input DNA 60 ng input DNA 
 
Figure 4-6 Performance of Bio-Rad ddPCR for the detection of KRAS mutation. 
Different total amount of input DNA mixture were analysed with dPCR – (a) 30ng total 
DNA, (b) 60 ng total DNA. The number of positive mutant molecules measured by dPCR 
assay is on the y-axis and the percentage of expected mutant molecules is on the x-axis. 
The number stated at the right corner of the plot is the maximum number of detected 
mutant molecules. Note that the graphs were fully based on a complete run that 
successfully detected normal and mutant molecules in all serial dilutions. And, the assay 
was designed for the detection of C>T base change (aa: G12D) in patient APGI 1953. The 
expected percentage of mutation detection is calculated by taking account of the cellularity 
and heterogeneity of the analysed sample (cellularity of the analysed sample x tumour 
variant allele frequency 50%). 
 
Quantification of ctDNA using recurrent KRAS mutation 
To determine if KRAS mutations are detectable in ctDNA, material from two patients was 
tested (APGI 1953 and APGI 2353). 
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Patient APGI 1953: This patient was tested for KRAS mutation of exon 2 of codon 12 (aa: 
G12D). The sequencing error rate obtained from the serial dilution of PGM sequencing 
experiment was 0.7% (Table 4-5). The assay was unable to detect the KRAS mutation in 
amplified plasma collected during post-operation and during chemotherapy. In this case, it 
suggests that the amount of ctDNA was less than 0.7%. Note that due to the availability of 
plasma, the quantification of plasma could not be performed on MiSeq or dPCR assay. 
 
 
Table 4-4 Summary of KRAS detection in plasma of patient APGI 1953  
 
   Reads  count for each base    
Description 
DNA mixture 
(% of tumour 
DNA) 
Amount of 
tumour 
DNA 
(corrected 
based on 
cellularity) A C G T 
# 
count 
Frequency 
mutation 
detection 
(%)* 
Expected % 
of mutation 
detection^  
KRAS_Nested 
Normal DNA 
(0%) 0 ng 1337 342736 1544 2411 348028 0.7% 0.0% 
KRAS_Nested 
Tumour DNA 
(100%) 6.9 ng 1225 184717 1678 158976 346596 46.3% 34.5% 
KRAS_Nested_cfDNA 
Post-
operation - 1238 268359 1462 1824 272883 0.7% NA 
KRAS_Nested_cfDNA 
During 
chemotherapy - 840 307275 489 434 309038 0.1% NA 
          
 
Summary table is based on serial dilution of tumour DNA in germline DNA from patient APGI 1953 with 
cellularity of 69%. Mutation was detected on KRAS exon 2, chr12 position 25398284, C>T, aa: G12D  
 
*Frequency mutation detection is the percentage of detected mutant molecules in a background of wild-
type DNA (sum of reads counts of the base change (T) divided by the sum of total reads counts at the 
target position (C+T) x 100%) 
 
^Expected percentage of mutation detection is calculated by taking into account of the cellularity and 
dilution of the analysed samples (cellularity of the analysed sample x tumour variant allele frequency 
50% x dilution factor) 
 
 
Patient APGI 2353: This patient contained a KRAS mutation in exon 3 of codon 60 and 61 
(aa:Q61K). Three cfDNA samples were collected during the patients disease course (pre-
operation, post operation 2nd day, and post operation 7th day). In all cases, the amount of 
cfDNA was limited, therefore the quantification assay was carried out using the two dPCR 
methods (i.e. Fluidigm and BioRad) as sequencing requires a high amount of DNA. Across 
the three cfDNA samples collected during the patients disease course (pre-operation, post 
operation 2nd day, and post operation 7th day), both dPCR assays showed no detection of 
mutant molecules in WGA plasma (data not shown). 
 
Multiple rounds of PCR are often performed to improve the sensitivity of mutation 
detection in the serums (Forshew et al., 2012). To increase the sensitivity, an extra round 
of 18 PCR cycles was performed on the WGA plasma DNA targeting KRAS region prior to 
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the quantification using dPCR assays. The PCR amplified WGA plasma was then 
quantified in five replicates on two separate dPCR assays using both Fluidigm and Bio-
Rad digital PCR system (data not shown). Even after an extra round of amplification, no 
mutant DNA molecules was detected in the population of circulating cfDNA suggesting 
that no mutant molecules was present in these samples or the level of mutant DNA were 
below the limits of detection of the instrument. In conclusion, no mutant DNA molecule was 
detected in plasma of patient APGI 2353 either in whole genome amplified samples or 
after multiple rounds of PCR.  
 
Overall, the quantification results either using sequencing or dPCR assays re-
emphasized the conclusion that there was little or no ctDNA present in the serum or 
plasma of patients APGI 1959, APGI 1953, and APGI 2353 and therefore hampered 
reliable detection. 
 
4.3.3 Level of CA 19.9 and tumour burden 
Here, I examined the timeline of these serum or plasma collected and the level of CA 19.9 
across disease stages of the three pancreatic cancer patients. CA 19.9 is the most widely 
used and investigated marker for pancreatic cancer. Elevated levels of CA 19.9 are often 
associated with advanced pancreatic cancer or an indication of recurrent disease. Notably, 
patient APGI 1959 presented the highest level of CA19.9 with an average of ~567 U/mL 
ranging from 39 to 2520 U/mL suggesting that this patient might have the highest tumour 
burden as compared to the other two patients (Supplementary Table 4-7). The level of CA 
19.9 of patient APGI 1953 was an average of ~82 U/mL ranging from 4 to 472 U/mL while 
average level of CA 19.9 of patient APGI 2352 was ~117 U/mL ranging from 16 to 267 
U/mL. It was noted that the level of CA 19.9 of patient APGI 1959 was about 4 – 7 times 
higher than the other two patients. Hence, this suggests that the detection and 
quantification of tumour specific mutation in the serum from patient APGI 1959 might be 
due to the high tumour burden. Furthermore, the tumour specific mutation was detected in 
serum, which was collected after the spread of cancer to the liver (Figure 4-7). In contrast, 
plasma samples obtained from patients APGI 1953 and APGI 2353 were collected before 
the metastasis (Table 4-5, Figure 4-7). This observation suggests the detected tumour 
specific rearrangements (somatic deletion) in the circulating cfDNA of patient APGI 1959 
could be derived from the liver metastasis sharing the same mutation with the primary 
pancreas tumour. Additionally, it might also suggest that the detection of mutant DNA 
molecules in the serum is more feasible in patients with metastatic disease. 
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Table 4-5 Summary of the analysed serum 
 
 
Patient 
Mutation 
(Position) 
Cellularit
y of the 
primary 
tumour 
Date of 
the serum 
collected 
Status of the 
serum 
collection 
Estimate
d level 
of CA 
19.9 
(U/mL) 
# of mutant 
molecules 
detected by 
dPCR 
Frequency of 
mutation 
detection by 
next 
generation 
sequencing  
APGI 
1959 
Deletion 
(chr10:81,937,8
66-131,680,191) 
83% 16/01/10 
After the 
diagnosis of liver 
metastasis 
~248-387 6 Did not perform 
APGI 
1953 
KRAS, C>T 
(chr12: 
25,398,284) 69% 
29/12/10 Post-op ~16-65 Did not perform 0.7 % (PGM) 
04/01/11 During chemotherapy ~16-65 
Did not 
perform 0.1% (PGM) 
APGI 
2353 
KRAS, GA>TT 
(chr12:25,380,2
77- 25,380,278) 
30% 
03/06/11 Pre-op ~254-267 0 
Did not 
perform 06/06/11 Post-op, 2
nd day ~254-267 0 
10/06/11 Post-op, 7th  day ~254-267 0 
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Figure 4-7 CA 19.9 levels across the 3 patients APGI 1959, APGI 1953, and APGI 
2353. Arrow and text in red indicate the date of serum collected. Arrow in blue indicates 
the treatment and disease status of individual patient. Text in green indicates metastasis 
of the disease. The line in the blue area of the graph indicates the timepoints of CA 19.9 
measurements. Supplementary Table 4-7 listed the value of CA 19.9 level.   
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4.4 Discussion 
The evidence of tumour-derived mutations within circulating cfDNA was reported decades 
ago (Schwarzenbach et al., 2011; Sorenson et al., 1994; Vasioukhin et al., 1994). The 
quantification of cfDNA could effectively distinguish between patients with tumours and 
healthy individuals or monitoring patients after surgery and during chemotherapy. Studies 
carried out by Leary et al. have successfully detected tumour specific mutations in serum 
or plasma and have shown their potential as personalized biomarkers to monitor cancer 
disease progression in breast, bone and colorectal (Leary et al., 2010; Leary et al., 2012).  
 
 In this chapter, I investigated the possibility of using tumour specific mutations as 
clinical biomarkers for pancreatic cancer patients to improve the detection of recurrence 
and therapy response. I used two approaches: 1) a personalised approach using somatic 
rearrangement and 2) a generic approach using recurrent mutation of KRAS gene that is 
identified in most pancreatic cancers. 
 
Personalised approach – somatic rearrangement 
The quantification of ctDNA using tumour specific rearrangement was tested on serum of 
patient APGI 1959 using digital PCR (Fluidigm and Bio-Rad) and showed positive 
detection of 6 mutant copies. Even though the level of CA 19.9 was extremely high and 
the patient had metastatic disease, the amount of ctDNA in the circulation was very low. 
Unfortunately, due to the availability of serum, we could not repeat the assessment using 
next generation sequencing to validate the positive detection.  
 
Generic approach – recurrent KRAS mutation 
Two different methods (next generation sequencing and digital PCR) were assessed to 
determine the detection limit of KRAS mutation using serial dilutions of tumours. The 
results showed that both benchtop sequencers (PGM and MiSeq) and digital PCR assays 
(Fluidigm and Bio-Rad) have the capacity to detect tumour specific mutation in serial 
dilutions of tumour. PGM could achieve a detection limit for mutant allele fraction at 0.7% 
with read depth of 350,000x while the detection limit of MiSeq was at 0.3% with a higher 
deep coverage of 600,000x. The result from MiSeq is within the range of frequency 
mutation detection limit of what have been previously reported by numerous studies (0.02 
- 2%) (Forshew et al., 2012; Narayan et al., 2012; Newman et al., 2014). The detection 
limits are varied across the different studies as they used different sequencing depth, 
algorithm as well as different cancer types was being analysed. However, based on the 
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results presented here, MiSeq would be more suitable for the quantification for KRAS 
mutation in ctDNA. However in this project, the MiSeq machine was acquired later, thus 
the quantification of ctDNA in patient APGI 1953 which initially performed using PGM, 
could not be repeated with the MiSeq as there was no extra DNA or plasma available.  
 
 With respect to dPCR, the detection limit could not be determined as we do not 
have enough normal DNA to include as control. However, the droplet dPCR (Bio-Rad) 
assays have shown that mutation detection increased when the amount of DNA input is 
higher. In contrast, the chip-based dPCR (Fluidigm) was limited by the input DNA attribute 
to the number of partitions and thus, lesser volume of the samples could be analysed. 
Regardless, both chip (Fluidigm) and droplet based (Bio-Rad) dPCR showed linear 
relationship with the expected frequency of mutation detection indicating the ability of 
these assays to quantify mutations in a single experiment.  
 
 During the quantification of ctDNA in patients APGI 1953 and APGI 2353, no KRAS 
mutation was detected in the cfDNA from plasma. Together with the result obtained from 
APGI 1959, it suggests that there was little or no tumour specific mutation in the serum or 
plasma across these three patients. The reasons why ctDNA was detected in patient APGI 
1959 and not patients APGI 1953 and patient 2353 could be due to the high CA19.9 level 
and the late stage disease when serum or plasma were collected. It was noted that the 
plasma collected from patients APGI 1953 and APGI 2353 were at the early stage of the 
disease (before liver metastasis) and these patients had a lower CA19.9 level with an 
average of ~82 and ~117 U/mL. In contrast, the serum collected from patient APGI 1959 
was at the later stage of the disease (presenting liver metastasis) and the patient had an 
extremely high CA19.9 level with an average of ~567 U/mL. The high level of CA19.9 
suggests higher tumour burden in patient APGI 1959, therefore increased the likelihood of 
mutation detection rate in the circulation. However, it could also be possible that the 
detected ctDNA in patient APGI 1959 may be derived from the liver metastasis, which 
shared the same mutation with the primary pancreas tumour. 
 
 Potential factors that may affect detection of tumour DNA in circulation and might 
explain why no ctDNA was detected in the two patients. 1) Nature of pancreatic tumour. 
Pancreatic tumours generally contain a large amount of stromal and fibrotic tissue, which 
results in low blood perfusion and a hypoxic environment, therefore reducing the chance of 
ctDNA to be released into the blood (Yu and Tannock, 2012). 2) The tissue structure of 
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pancreas. Fragmented tumour DNA leaving the pancreas may get processed and broken 
down by the liver before entering the bloodstream (Nussey and Whitehead, 2001), 
therefore reducing the ability to detect tumour specific mutation in the circulation. 3) 
Disease stage. A recent study carried out by Bettegowda et al. (Bettegowda et al., 2014) 
analysed the detection of ctDNA in early and late stage of human cancers including 
pancreatic cancer in a large cohort of 640 patients. They reported that the detection rate of 
ctDNA in the blood samples was correlated with the disease stage of cancer and the 
concentration of ctDNA increases as the disease progressed. From the 34 plasma 
samples from pancreatic cancer, the authors detected ctDNA in approximately 90% of the 
cases with metastatic disease, and only approximately 50% of the cases with localised 
pancreatic cancer. Their findings suggest that at this current stage, the detection of ctDNA 
is more feasible in patients with metastatic disease, which agree with the results presented 
in this chapter. In the context of pancreatic cancer, the quantification might be more 
suitable to test recurrent disease, which metastasized away from the pancreas. 4) The 
volume of serum or plasma used to extract cfDNA may be also crucial. Bettegowda et al. 
(Bettegowda et al., 2014) used 5 mL of plasma, which is double the amount of plasma or 
serum used in this study. 
 
 Furthermore, this project also contained several logistic limitations. These include 
genomic contamination of several serum DNA samples, the slow progress of recruitment 
of new patients with ctDNA and the need to draw more blood from patients. 
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4.5 Supplementary Material 
 
Supplementary Table 4-1 Summary of serum or plasma DNA received  
Patient Garvan ID Type 
Volume of initial 
serum/plasma 
(uL) 
Volume 
received 
(uL) 
Quantity 
(ng /uL) Quality 
APGI-1830 8048277 Post op 955 20 0 Fail 
APGI-1830 8048278 Post op 955 <10 0 Fail  
APGI-1830 8048276 Post-op 955 20 0 Fail  
APGI-1953 8047164 During 
chemotherapy 
900 20 0.89 Pass 
APGI-1953 8047172 Post-op 900 20 0.65 Pass 
APGI-1953 8047973 Pre-op 840 20 0 Fail 
APGI-1953 8047168 Pre-op 430 20 0 Fail 
APGI-1953 8048813 Pre-op 900 25 0 Fail 
APGI-1953 8047974 Pre-op 885 25 0 Fail 
APGI-1953 8047165 During 
chemotherapy 
900 8 0.32 Pass 
APGI-1953 8047173 Post-op 900 12 0.14 Pass 
APGI-2302 8047990 Post-op 840 20 2.3 Fail 
APGI-2302 8047993 Post-op 840 20 1.01 Fail 
APGI-2302 8047976 Pre-op 840 20 0 Fail 
APGI-2302 8047976 Pre-op 1755 20 0 Fail 
APGI-2353 8048285 Post-op (2 days) 1755 20 5 Pass 
APGI-2353 8048286 Post-op (2 days) 1755 20 1.24 Pass 
APGI-2353 8048287 Post-op (2 days) 1755 <10  5.3 Pass 
APGI-2353 8048298 Post-op (60 
days) 
1755 20 0.3 Pass 
APGI-2353 8048300 Post-op (60 
days) 
1755 <10  0.3 Fail 
APGI-2353 8048299 Post-op (60 
days) 
1755 20 0 Fail 
APGI-2353 8048291 Post-op (7 days) 1755 20 1.62 Pass 
APGI-2353 8048292 Post-op (7 days) 1755 20 2.44 Pass 
APGI-2353 8048293 Post-op (7 days) 1755 <10  2.33 Pass 
APGI-2353 8048279 Pre-op 1755 20 1.50 Pass 
APGI-2353 8048280 Pre-op 1755 20 0.50 Pass 
APGI-2353 8048281 Pre-op 1755 <10  1.58 Pass 
APGI-1959 8016633 During 
chemotherapy 
500 NA NA Pass 
 
Pre-op: It refers to blood collected before operation. 
Post op: It refers to blood collected after operation (indicates the number of days after operation). 
 
Pass: It indicates that the size of the serum or plasma DNA lies within expected range between 130 and 200 
bp. Fail: It indicates that the serum or plasma DNA is contaminated with genomic DNA that could due to cell 
lyse 
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Supplementary Table 4-2 Summary of the amount of serum or plasma DNA used throughout the attempt of quantification 
Patient 
id 
Description of 
the 
serum/plasma 
Quantity of 
serum/plasma DNA 
received (volume) 
Quantity of 
serum/plasma DNA 
used in whole 
genome 
amplification 
Quantity of 
amplified 
serum/plasma 
DNA (volume) 
Quantity of 
amplified 
serum/plasma DNA 
used per nested 
PCR reaction 
Quantity of 
amplified 
material used 
per digital PCR 
run (Fluidigm & 
Bio-Rad) 
Quantity of 
amplified material 
used per 
sequencing run 
(PGM & MiSeq) 
APGI 
1959 
During 
chemotherapy 
0.1 ng (NA) 
 
NA 24 ng (1 uL) NA 24 ng NA 
APGI 
1953 
Post-operation 13 ng (20 uL) ~ 9 ng 46.2 ng (14 uL) 2 ng NA 10 ng 
APGI 
1953 
During 
chemotherapy 
17.8 ng (20 uL) ~ 9 ng 46.2 ng (14 uL) 2 ng NA 10 ng 
APGI 
2353 
Pre-operation 30 ng (20uL) ~ 20 ng 360 ng (15 uL) 2 ng 36 ng NA 
APGI 
2353 
Post-operation 
(after 2 day) 
24.8 ng (20 uL) ~ 20 ng 381 ng (15 uL) 2 ng 36 ng NA 
APGI 
2353 
Post-operation 
(after 7 day) 
32.4 ng (20uL) ~ 20 ng 435 ng (15 uL) 2 ng 36 ng NA 
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Supplementary Table 4-3 Details of primers and barcodes used for KRAS mutation 
detection in next generation sequencing  
Description (Patient ID) Primer sequence 
Barcode sequence for 
PGM 
Barcode sequence for 
MiSeq 
Nested PCR  >IonXpress_001 
CTAAGGTAAC 
 
>IonXpress_002 
TAAGGAGAAC 
 
>IonXpress_003 
AAGAGGATTC 
 
>IonXpress_004 
TACCAAGATC 
 
>IonXpress_005 
CAGAAGGAAC 
 
>IonXpress_006 
CTGCAAGTTC 
 
>IonXpress_007 
TTCGTGATTC 
 
>IonXpress_008 
TTCCGATAAC 
 
>IonXpress_009 
TGAGCGGAAC 
 
>IonXpress_010 
CTGACCGAAC 
 
>IonXpress_011 
TCCTCGAATC 
 
>IonXpress_012 
TAGGTGGTTC 
 
>IonXpress_013 
TCTAACGGAC 
 
>IonXpress_014 
TTGGAGTGTC 
 
>IonXpress_015 
TCTAGAGGTC 
 
>IonXpress_016 
TCTGGATGAC 
>MID_1 
ACGAGTGCGT 
 
>MID_2 
ACGCTCGACA 
 
>MID_3 
AGACGCACTC 
 
>MID_4 
AGCACTGTAG 
 
>MID_5 
ATCAGACACG 
 
>MID_6 
ATATCGCGAG 
 
>MID_7 
CGTGTCTCTA 
 
>MID_8 
CTCGCGTGTC 
 
>MID_10 
TCTCTATGCG 
 
>MID_11 
TGATACGTCT 
 
>MID_13 
CATAGTAGTG 
 
>MID_14 
CGAGAGATAC 
 
>MID_15 
ATACGACGTA 
 
>MID_16 
TCACGTACTA 
 
>MID_17 
CGTCTAGTAC 
 
>MID_18 
TCTACGTAGC 
 
>MID_19 
TGTACTACTC 
 
>MID_20 
ACGACTACAG 
 
 >MID_21 
CGTAGACTAG 
 
>MID_22 
TACGAGTATG 
 
>MID_23 
TACTCTCGTG 
1st round 
(APGI 1953) 
F:  
5’- ATTCGTCCACAAAATGATTC 
R: 
5’- GTTCTAATATAGTCACATTTTCATT 
 
(APGI 2353) 
F:  
5’- CAAAGAAAGCCCTCCCCAGT 
R:  
5’- AGGATTCCTACAGGAAGCAAG 
 
2nd round 
(APGI 1953) 
F:  
5’- TATCGTCAAGGCACTCTTGC 
R:  
5’- GCCTGCTGAAAATGACTGAA 
 
(APGI 2353) 
F:  
5’- TACTGGTCCCTCATTGCACTGT 
R:  
5’- TGATGGAGAAACCTGTCTCTTGGA 
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Supplementary Table 4-4 Details of primers and probes used for tumour specific 
mutations detection in dPCR 
Patient ID APGI 1959 APGI 1953 APGI 2353 
Event type Deletion KRAS codon 12 KRAS codon 60, 61 
Event size (bp) 50,000 NA NA 
Base change NA Codon 12; C>T Codon 60, 61; GA>TT 
Position chr10:81,937,866-
131,680,191 
chr12: 25,398,284 
 
chr12:25,380,277- 25,380,278 
aa change NA G12D Q61K 
Primes sequence 
(5’-) 
F: 5’ - 
TCCGCTTGGTACAG
GGAGAAGCA 
 
R: 5’- 
GGGCTCCAGTTAAA
ACGGTTGATCCC  
 
F: 5’- 
GCCTGCTGAAAATGA
CTGAATATAAACT 
 
R: 5’- 
GCTGTATCGTCAAGG
CACTCTT 
 
 
F: 5’- 
CATGTACTGGTCCCTCATTGC
A 
 
R: 5’ - 
GATGGAGAAACCTGTCTCTTG
GAT  
 
Probes sequence FAM 5’-
TGGCCGGGAGAGTC
CCAACAAAAAA 
 
 
FAM 5’-  
TTGGAGCTGATGGCG
TA 
 
VIC 5’- 
TTGGAGCTGGTGGCG
TA 
FAM 5’- 
TGTACTCCTCTTTTCCTGCTG 
 
VIC 5’- 
TGTACTCCTCTTTTCCTGCTG 
Amplicon size 180 bp 78 bp 78 bp 
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Supplementary Table 4-5 Analysis of ctDNA using QX100™ Droplet Digital PCR 
System 
Sample Dilution 
Data 
Quality  Concentration Copies/rxn 
Poisson 
Conf 
Min 
Poisson 
Conf 
Max Positives Negatives 
Primary 
tumour 
APGI 1959 1:100 0 0 0 0 0.278 0 11850 
Serum 
APGI 1959 
1:1 99.5 0.459 9.18 0.18 0.938 6 14368 
1:2 99.7 0.255 5.1 0.0606 0.677 3 12913 
1:5 0 0 0 0 0.503 0 6549 
1:10 0 0 0 0 0.262 0 12551 
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Supplementary Table 4-6 Summary of dPCR assay using QX100™ Droplet Digital 
PCR system 
   VIC signal 
(Wild type) 
FAM signal 
(Mutant) 
  
Total 
amount 
DNA 
DNA 
mixture 
Tumour 
DNA per 
reaction # Estimated targets^ # Estimated targets^ 
Mean of 
mutation 
detection 
(%)§ 
Expected % 
of mutation 
detection♮ 
   Run 1 Run 2 Run 1 Run 2  Mean   
30 ng 1:5  
(20%) 6.9 ng 4361 0* 319 0* - 6.28% 6.9% 
 1:25  
(4%) 1.4 ng 4396 4215 71 69 
70 
±1.4 1.60% 1.4% 
 1:125 
(0.8%) 0.276 ng 4871 3476 20 9 
14.5 
±7.8 0.35% 0.3% 
 1:625 
(0.16%) 0.0552 ng 4859 4502 4 4 
4 
± 0 0.082% 0.0552% 
 1:3,125 
(0.032%) 0.011 ng 4357 3723 3 1 
2 
±1.4 0.069% 0.0110% 
60 ng  1:5  
(20%) 6.9 ng 472* 6890 34* 570 - 7.64% 6.9% 
 1:25  
(4%) 1.4 ng 8592 6577 136 106 
121 
±21.2 1.57% 1.4% 
 1:125 
(0.8%) 0.276 ng 8629 7785 44 26 
35 
±12.7 0.42% 0.3% 
 1:625 
(0.16%) 0.0552 ng 8169 7656 23 5 
14 
±12.7 0.177% 0.0552% 
 1:3,125 
(0.032%) 0.011 ng 7328 7000 11 1 
6 
±7.1 0.084% 0.0110% 
          
 
Analysis table is based on DNA mixture of patient APGI 1953 with cellularity of 69%. Mutation was 
detected on KRAS exon 2, chr12 position 25398284, C>T using QX100™ Droplet Digital PCR system. 
 
^Estimated targets estimated number of molecules present in a reaction determined by QX100™ Droplet 
Digital PCR software.  
 
§Mean of mutation detection is the percentage of mutant molecules in a background of wild type DNA 
(sum of estimated targets for mutant molecules divided by sum of estimated targets for wild type and 
mutant molecules x 100%)  
 
 The expected percentage of mutation detection was calculated by taking into account with the cellularity, 
heterogeneity and dilution factor of the analysed samples (tumour variant allele frequency 50% x 
cellularity of the analysed sample x dilution factor) 
 
*Failed run or errors generated during set up and preparation of the assay.  
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Supplementary Table 4-7 Levels of CA 19.9 of the 3 analysed patients across their 
clinical journey^ 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^ Note that the level of CA 19.9 corresponds to Figure 4-5. 
  
APGI 2353 – 
Date of measurement 
Level 
(U/mL) 
26/05/11 267 
27/05/11 254 
2/11/11 16 
26/06/12 24 
14/08/12 23 
  
APGI 1959 –  
Date of measurement 
Level 
(U/mL) 
   1/02/09 39 
17/03/09 594 
2/11/09 41 
14/12/09 143 
4/01/10 248 
11/02/10 387 
17/03/10 2520 
  
 
APGI 1953 –  
Date of measurement Level (U/mL) 
21/04/09 4 
26/06/09 9 
30/07/09 8 
18/08/09 4 
14/09/09 5 
13/10/09 7 
10/11/09 10 
26/06/10 20 
5/10/10 23 
15/12/10 65 
18/04/11 16 
16/05/11 11 
23/07/11 21 
1/11/11 39 
9/02/12 393 
12/03/12 453 
20/03/12 472 
9/04/12 161 
7/05/12 61 
4/06/12 40 
9/07/12 26 
24/07/12 34 
1/11/12 14 
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5 Chapter 5 
 
Final conclusion and discussion 
 
5.1 Summary  
Throughout this thesis, I presented a comprehensive study of somatic rearrangements in 
primary pancreatic tumours and focussed on three different aspects: the exploration of 
genomic technologies and computational methods to detect and verify somatic 
rearrangements, analysis of somatic rearrangements and breakpoints, and the utility of 
tumour specific rearrangements and mutations in personalized genomic medicine.   
 
In Chapter 2, I established a high throughput workflow to rapidly verify somatic 
rearrangements and identified exact breakpoints to base pair resolution in primary tumours 
using genomic and computational tools. Highlights: The advantages of this high 
throughput workflow include (i) the utilization of benchtop next generation sequencing (Ion 
Torrent PGM and Illumina MiSeq) to replace conventional Sanger sequencing, which 
mitigated the concern of PCR product size allowing primers to be designed for more 
events; (ii) the integration of bioinformatics tools and next generation sequencing based 
methods, which greatly increased the speed and volume of the verification process; and 
(iii) the accuracy of the next generation sequencing methods was comparable to the 
conventional Sanger sequencing method. Furthermore, this workflow is applicable to both 
long mate pair and pair end sequencing data as the qSV tool has the ability to identity 
structural rearrangements from SOLiD and Illumina sequencing platforms. This work has 
been published in BioTechniques Report as a method article in early 2014 (Quek et al., 
2014).  
 
In Chapter 3, I described the spectrum of somatic rearrangements and breakpoints 
detected in 120 primary pancreatic tumours. The analyses conducted include the 
characterization of breakpoint junctions, the examination of breakpoint patterns at the 
junctions using the information obtained from split contig alignment as well as searching 
for DNA enrichment patterns from the reference genome surrounding the breakpoint. 
Highlights: A total of 10,074 high confidence somatic rearrangements were identified from 
120 pancreatic primary tumours. Pancreatic cancer is heterogeneous disease as each 
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pancreatic cancer genome displays distinct numbers and patterns of genomic breakpoints. 
The exact breakpoints were resolved in 95% of the somatic rearrangements. The majority 
of the breaks exhibited 74.8% microhomology and approximately 67.0% of these 
microhomology rearrangements contained short overlapping bases of 1 to 5 bp, which 
suggest that NHEJ might be the predominant DNA repair mechanism in pancreatic cancer. 
Pancreatic tumours associated with BRCA mutations and/or a high contribution of the 
BRCA mutational signature showed a higher frequency of somatic breakpoints with 
microhomology length of 1 to 5 bp and lower frequency of blunt end (0 bp) when 
compared to BRCA wild type or low BRCA mutational signature tumours. A similar pattern 
was also observed in a cohort of ovarian tumours. Together, these datasets suggest that 
different NHEJ pathways were utilised depending on the BRCA mutation status. 
Furthermore, the BRCA deficiency tumours that were associated with HR defective 
pathway seem to favour the restoration of the breaks by ‘error-prone’ NHEJ pathway. Thus, 
the identification of breakpoints with microhomology may indicate the process of defective 
HR pathway in a subgroup of pancreatic tumours and could response to PARP1 inhibitors.  
 
In addition, the analysis of the DNA sequences surrounding the breakpoints 
revealed strong signals of A+Ts rich regions suggesting that the formation of somatic 
rearrangements in pancreatic cancer could be in part mediated by either retrotransposition 
activity or chromosomal fragile sites, however these findings need to be further 
investigated. Taken together, the results presented in Chapter 3 provide insights into the 
complexity of breakpoints patterns in pancreatic cancer genomes. The different 
composition of event types and differences between the breakpoint characteristics across 
the pancreatic cancer genomes may suggest that the somatic rearrangements in 
pancreatic tumorigenesis could be formed by multiple DNA repair mechanisms.  
 
The categorization of thousands of chromosomal somatic rearrangements across 
120 pancreatic primary tumours revealed that each cancer genome harbours a diversity of 
somatic structural rearrangements and mutations. Therefore, it was hypothesized that 
these tumour specific alterations could be used as potential cancer biomarkers for clinical 
utility.  
 
In Chapter 4, I outlined a framework that combined tumour specific somatic 
rearrangements (personalized) and recurrent KRAS mutation (generic) to quantify ctDNA 
in serums or plasma collected from pancreatic cancer patients following a course of 
 135 | P a g e 
therapy. The aim was to identify an alternative approach utilising verified somatic 
rearrangements and mutations as low invasive biomarkers in the serum or plasma of 
pancreatic cancer patients to trace the course of disease or during cancer treatment. This 
work could potentially show the use of next generation sequencing technology as a 
diagnostic tool in the clinic. Highlights: PCR based and sequencing based methods have 
demonstrated the capacity of detecting and quantifying ctDNA. In this subset of pancreatic 
cancer patients, the detection limits for sequencing and digital PCR methods was <1%. 
Unfortunately, there was little or no ctDNA detected in the serum or plasma samples from 
the cases studied. Perhaps due to the nature of pancreas cancer, the tissue structure of 
pancreas, disease progression, and volume of plasma and serum collected for DNA 
isolation have affected the quantification of tumour specific mutation in the circulation.  
 
 Overall, the results from Chapter 4 showed the following limitations and challenges: 
(1) the limited amount of cfDNA obtained from <2 mL of blood has imposed a challenge in 
quantifying ctDNA; (2) the area of circulating DNA is still at the early stage, the current 
techniques and technologies used for isolation and detection of ctDNA may have limited 
capacity and sensitivity to detect mutations that represent 0.01% of the total population of 
cell free circulating DNA; (3) most of the pancreatic cancer patients are diagnosed at late 
stage and have a median survival of 6 months, this increases challenge in recruiting more 
samples to follow the disease course in pancreatic cancer patients. 
 
5.2 Future studies 
The current analyses have provided a foundation, however, we could still improve the 
methods and analyses to further explore the data and better understand the process of 
somatic rearrangements formation in pancreatic carcinogenesis and the clinical utility of 
such rearrangements.  
 
Chapter 2 – A High throughput workflow to rapidly detect and identified somatic 
rearrangements breakpoints 
The high throughput workflow still required manual steps to confirm potential structural 
rearrangements. Therefore, the workflow can be improved by the following: (1) Elimination 
of the gel electrophoresis step. The PCR amplification of tumour and matched normal DNA 
from individual patient can be barcoded, pooled and subsequently sequenced on benchtop 
sequencing platforms. After the assembly, the somatic events can be determined by 
selecting the breakpoints identified in tumour and not in normal. Hence, this procedure can 
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further reduce the amount of time and labour for the analysis of somatic rearrangements. 
(2) Complete removal of wet lab verification such as PCR and gel electrophoresis. The 
evaluation of the sensitivity and accuracy of identifying somatic rearrangements in cancer 
can be validated by using multiple callers and different sequencing platforms (such as 
HiSeq X and NextSeq 500).  
 
Chapter 3 – Characterisation and patterns of somatic breakpoints 
This chapter has reported a comprehensive catalogue of somatic rearrangements and 
breakpoint characteristics of pancreatic cancer. The breakpoint characteristics have 
provided an insight into the potential operative mechanisms of generating somatic 
rearrangements. To further explore the formation mechanisms of somatic rearrangements, 
future studies could consider other genomic factors that might impact on the numbers and 
distribution of breakpoints in the genome and these were previously suggested by Drier et 
al. (Drier et al., 2013). Genomic factors include replication time, transcription rate and GC 
content. In their study, they have shown that these factors can differ by tumour types and 
the pattern of breakpoints might explain cellular processes that generate or repair the 
somatic rearrangements. The identification of breakpoints with a higher frequency of 
microhomology in BRCA mutated and high BRCA mutational signature samples suggests 
that this group of pancreatic tumours might respond to PARP inhibitors and/or DNA 
damaging agents. However to confirm this, further studies would need to be performed 
using patient material from those that did and did not respond to PARP inhibitors and/or 
DNA damaging agents.  
 
 The analysis of the DNA sequence surrounding the breakpoints indicates the signal 
of A+Ts enrichment in the regions around the breakpoints. Further analysis to pinpoint the 
potential mechanism is required so that we can clarify that A+Ts rich sequences are 
associated with retrotransposons and/or fragile sites. Analysis could include the study of 
the relative distance of A+Ts motifs from the exact breakpoint location or mapping the 
DNA sequences surrounding the breakpoints to repeats database and/or known fragile 
sites regions to further elucidate the mechanism. Furthermore, the DNA patterns at the 
breakpoints allow additional analysis such as methylation sites, histone marks and tandem 
repeats. All these analyses together may give us more clues on the operative mechanisms 
in pancreatic cancer.   
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Chapter 4 – Analysis of circulating tumour DNA in pancreatic cancer patients 
Despite the slow recruitment of patients, here is some of the potential future work to 
address the limitations that I have encountered when detecting ctDNA in pancreatic 
cancer:   
 
(1) Increase the starting volume of the blood to maximise the sensitivity of detecting 
ctDNA (as currently we were only collecting approximately <2 mL of blood) and the volume 
of blood withdraw should be consistent throughout the course of study.  
 
(2) Improve isolation methods to isolate ctDNA. The use of circulating cfDNA is still 
at its early stage, as the field matures, apart from QIAamp DNA Blood Kit (Qiagen, Inc.) 
which is widely used for isolating circulating cfDNA from serum or plasma, it is possible 
that more commercial kits or improvements in existing techniques become available and 
bring more options to better isolate ctDNA. 
 
 (3) To improve rare allele enrichment, we could evaluate the COLD-PCR (co-
amplification at lower denaturation temperature PCR) method. As suggested, COLD-PCR 
prior to sequencing or genotyping assays can improve the ability of detecting mutation by 
50-fold (Milbury et al., 2012) 
   
 (4) The use of exosomes as biomarkers. Previous study has demonstrated that 
more than 10 kb fragments of genomic DNA spanning across KRAS and TP53 mutations 
were identified in the serum exosomes of patients with pancreatic cancer (Kahlert et al., 
2014). Exosomes are very stable in various conditions, and the genetic materials are 
protected against degradation and denaturation in extracellular environment by the vehicle 
(Taylor and Gercel-Taylor, 2008). Thus, exosomes might be a promising biomarker for 
pancreatic cancer. 
 
 
5.3 Closing remarks  
This is an exciting phase of cancer genomics as sequencing embarks on a new journey of 
how we think about cancer and cancer treatment. In this thesis, I presented a high 
throughput method to verify rearrangements, conducted analysis to explore factors that 
may give us clues about the differences in numbers and distribution of somatic 
rearrangements in pancreatic cancer and finally explored the clinical utility of these events 
in patients with pancreatic cancer. 
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